[{"article": "Lipton directs the Montefiore Headache Center at the Albert Einstein College of Medicine in the Bronx.\n\"There is a lot of unmet medical need out there in the treatment of migraine,\" he says.\n\"Some people don't tolerate the drug treatments very well and others just want to avoid them.\"\nMarch 3, 2010 -- A handheld device that magnetically zaps pain may be a promising new treatment for patients with a common type of migraine.\nDrugs commonly used in the treatment of severe headaches are generally not considered effective in the aura phase of migraine attacks, and many patients want to treat their migraines without using drugs, neurologist and headache specialist Richard B. Lipton, MD, tells WebMD.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this device is pending FDA approval and not yet available.\u00a0 ", "answer": 1}, {"article": "However, they say these findings \u201craise questions that warrant investigation\u201d and call for verification in randomised studies \u201cbefore recommending a change to current practice.\u201d\n\nNotes to Editors\n\n Research: Antenatal nutritional supplementation and autism spectrum disorders in the Stockholm youth cohort: population based cohort study\n\n Journal: The BMJ\nThe researchers stress that their findings cannot establish cause and effect, but say they raise questions about a possible association that warrant further investigation.\nThere was no consistent evidence that either iron or folic acid use were associated with a reduced risk of ASD.\nGiven the current understanding and strength of evidence supporting the importance of nutritional supplementation during pregnancy, \u201cit is impossible to imagine that these results, on their own, should change current practice,\u201d they write.\nAfter adjusting for several potentially influencing factors in both mothers and children, the researchers found that multivitamin use, with or without additional iron and/or folic acid, was associated with a lower likelihood of child ASD with intellectual disability relative to mothers who did not use folic acid, iron, and multivitamins.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release doesn\u2019t mention availability of multivitamins, but we concede that supplements are as widely available as are drug stores.", "answer": 2}, {"article": "Bethany, who manages occupational therapists for a nursing-home chain, and Jay, a rural mail carrier, shuttled between the Twin Cities visiting their daughters.\nIt was no longer producing the CD19 protein, which meant her modified T cells could no longer recognize the disease.\nThe majority have gone into remission, although some have had their cancer return.\nUnlike other cancer advances, it is being tested widely in children because of its stunning effectiveness in ALL, the most common pediatric cancer.\nIn the past few years, however, breakthroughs have led to the development of two types of immunotherapy \u2014 checkpoint inhibitors and CAR T cells \u2014 that are generating enormous excitement.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that this therapy is experimental, and currently available only in trials.", "answer": 1}, {"article": "\"There was a trend toward less severe psoriasis severity in people taking statins,\" says researcher Adam Perry, a fourth-year medical student at Emory University in Atlanta.\nAnd no one should start taking statins in an attempt to ward off psoriasis symptoms, doctors stress.\nIn a study of 232 people taking medication for psoriasis, those who also took statins had fewer of the thick, red, scaly, itchy patches that are the hallmark sign of psoriasis, compared with people who didn't take the cholesterol-lowering drugs.\nThe study is preliminary and doesn't prove cause and effect.\nAlready linked to a reduced risk of rheumatoid arthritis, diabetes, multiple sclerosis, and cancer, statins also may help to improve symptoms of psoriasis, researchers report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While statins are in widespread use, the story never emphasized that statins are not approved for treating psoriasis. ", "answer": 0}, {"article": "Dennis believes the ReavillMED CV shows a \"tremendous amount of promise,\" and he wants to test the first 50 catheters Reavill can provide.\nIt can be inserted in a nonsterile environment such as an emergency room.\nThe catheter is inserted into the arm and travels to the heart within 20 to 30 seconds via the bloodstream.\nOf those, between 28 and 50 percent die, according to the National Institute of General Medical Sciences.\nHe plans to bear the cost of any prostheses the veterans need to work on the catheters.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not clearly explained.\u00a0 Is anyone using this catheter clinically right now?", "answer": 0}, {"article": "\"This result suggests that adequate pain management should be an important goal of care, even after minor outpatient surgery, and that more effective pharmacologic and nonpharmacologic strategies should be explored,\" writes Dr. Naveen Poonai, Clinician Scientist, Lawson Health Research Institute, and Associate Professor, Emergency Medicine, Department of Paediatrics, Schulich School of Medicine & Dentistry, Western University, with coauthors.\nPain scores for children in both the oral morphine and ibuprofen groups were similar, but the children receiving oral morphine reported more adverse effects, such as nausea, vomiting, drowsiness, dizziness and constipation.\n\"Oral morphine versus ibuprofen administered at home for postoperative orthopedic pain in children: a randomized controlled trial\" is published October 10, 2017.\nOral morphine use at home has not been previously studied in children who have had minor surgery nor has it been compared with ibuprofen.\n\"Morphine did not provide superior analgesia, but was associated with significantly more adverse effects, making ibuprofen a better analgesic option,\" write the authors.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Just like with cost, we don\u2019t get information about how available oral morphine is. However, it seems safe to assume it\u2019s widely available with a prescription.", "answer": 2}, {"article": "The blisters heal in a week or two to form crusty scabs that eventually fall off.\nIf you\u2019re lucky you may detect the onset of shingles before the rash appears.\nThe shot itself is painful and can cause a sore arm for a day or two.\nIt is a painful infection of a single sensory nerve on one side of the body that can occur almost anywhere but most commonly involves the torso or face.\nMore than half the cases of PHN affect people over 60.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s available, and at least partly covered. The story makes this clear.", "answer": 1}, {"article": "In a small safety study to ensure that modafinil didn't make cocaine worse, some users found the once-a-day pill blocked that high.\nThe prospect of that double-whammy has the National Institutes of Health spending $10.8 million researching modafinil as a potential cocaine treatment.\nThe main side effect so far: insomnia, not surprising as modafinil is sold today to help narcolepsy patients fend off that neurologic disease's sudden sleep attacks.\nIn addition to blunting cocaine's notorious cravings, modafinil might also counter the damage that cocaine wreaks on users' brain circuits _ damage that in turn fuels the cycle of addiction.\nWASHINGTON -- The hottest topic in cocaine addiction is another drug _ a medicine already sold to wake up narcoleptics.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While modafinil is \u201clegal\u201d, it is still only FDA approved to treat narcolepsy and some cases of obstructive sleep apnea. The drug is also approved to treat shift work sleep disorders (i.e. the inability to adjust sleep hours due to overnight shift work), as this CNS stimulant has fewer side effects than caffeine or amphetamines. It is not yet approved to treat cocaine addiction. While the story explains the drug\u2019s current availability, it could have emphasized more clearly that the new use is still an unapproved use. Nonetheless, we give this a satisfactory score because of the cautions included in the story. ", "answer": 1}, {"article": "Newby and his team assessed how CTCA affected symptoms and quality of life six weeks and six months after the scan for 4,146 patients with suspected angina due to coronary heart disease.\nThe findings were similar when it came to changes in symptoms during follow-up.\nAlthough getting CTCA is associated with a lower likelihood of having a heart attack later on, its effects on symptoms and quality of life may vary, the researchers note in the journal Heart.\nConversely, knowing the cause of your symptoms is due to coronary heart disease and patients undergo treatment for it, is also very helpful,\u201d he said by email.\n\u201cMuch like screening tests for cancer, being told you have heart disease does not make the patient feel better,\u201d he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story refers to CTCA as an available testing method.", "answer": 1}, {"article": "Article reference: R.M.\nOf those, about half (or 593 women) received IV fluids at a rate of 250 milliliters per hour, and the other half (622 women) received fluids at the lower rate of 125 milliliters per hour.\nThis study suggests that IV fluids could help women maintain hydration at appropriate levels, reduce the likelihood of c-section, and decrease length of labor,\" says Dr. Berghella.\nEven low levels of dehydration can seriously compromise normal physiological function, yet recent studies looking at hydration in laboring women via the rates of intravenous (IV) fluid showed conflicting results.\nThe higher fluid rate also reduced the overall time of labor by an average of 64 minutes, and shortened the pushing phase by nearly 3 minutes, on average.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release suggests that some obstetricians already do \u2014 and more should \u2014 provide higher levels of fluids during labor.", "answer": 1}, {"article": "The potential use of psilocybin in patients diagnosed with life-threatening diseases comes at a moment when medical care at the end of life is a subject of growing concern among patients and physicians. Research finds it's still common for dying patients to get painful and futile procedures. Palliative and hospice care, both aimed at easing the discomfort of the seriously ill, are growing specialties in American hospitals. An increasing number of patients, meanwhile, are demanding the right to die with a physician's help.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a good job here. For example, the story notes: \u201c[F]inding drugs like psilocybin effective is by no means the final hurdle to their widespread availability. None are currently in production, and no for-profit pharmaceutical company would likely invest millions of dollars to bring to market a pill intended effectively for one-time use.\u201d Well done.", "answer": 1}, {"article": "Fetal death, or intrauterine fetal demise (IUFD), affects 30,000 women each year in the United States.\n\"This study has shown that the EFT can also be an important tool for patients with recurrent pregnancy loss,\" he said.\nThe results are published in the current issue of Fertility & Sterility, the international journal of the American Society for Reproductive Medicine.\n\"We are very pleased to find that these results reinforce the evidence that progesterone could be a very beneficial, inexpensive, and safe treatment for many women with a history of recurrent pregnancy loss,\" said Stephenson.\n\"In this subset of women experiencing multiple early miscarriages, we assume that their embryos were literally starving to death,\" Kliman added.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Progesterone is widely available, but what about the EFT? \u00a0We don\u2019t have any idea after reading this news release. We found no evidence relating to EFT in a review of clinical reproductive medicine guidelines.", "answer": 0}, {"article": "The Ache: Nearly 5,000 people a year die from choking in the U.S., according to the nonprofit National Safety Council.\n\nThe Claim: Two new easy-to-use devices work like plungers to suck out obstructions in the airway, providing another option if standard treatment\u2014such as abdominal thrusts developed in 1974 by Henry Heimlich\u2014fail to clear the airway, say the companies who sell them.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It sounds like the devices are already available:\nOn the market less than two years, neither LifeVac nor Dechoker has published evidence of successful uses in humans.", "answer": 1}, {"article": "The study\u2019s conclusions contrast with those of a report last year by the United States Preventive Services Task Force, an independent group that issues guidelines on cancer screening, questioning the benefit of screening women younger than 50.\nThe new study took advantage of circumstances in Sweden, where since 1986 some counties have offered mammograms to women in their 40s and others have not, according to the lead author, Hakan Jonsson, professor of cancer epidemiology at Umea University in Sweden.\nTheir paper is published online in the journal Cancer and will be presented on Friday at a meeting sponsored by the American Society for Clinical Oncology and five other organizations.\nBut their results were greeted with skepticism by some experts who say they may have overestimated the benefit.\nThe study\u2019s authors include Dr. Stephen Duffy, an epidemiologist at the University of London, and Dr. Laszlo Tabar, professor of radiology at the University of Uppsala School of Medicine in Sweden, who have long been advocates of mammography screening.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe availability of mammography was not explicitly addressed, but we can\u2019t criticize the story for that.\u00a0 Instead, we give a Not Applicable score for this criterion. ", "answer": 2}, {"article": "For more information on Hologic, visit www.hologic.com.\nThis has the potential to provide health systems and insurance companies with significant cost savings, reduce patient stress and expenses, and alleviate challenges for referring physicians who are tasked with relaying mammography results to their patients.\"\nThe actual effect of the use of the systems can only be determined on a case-by-case basis depending on the particular circumstances and patient in question.\n\"This new analysis confirms that Genius\u2122 3D MAMMOGRAPHY\u2122 exams reduce unnecessary follow-up exams in dense-breasted women.\nThese key benefits of 3D MAMMOGRAPHY\u2122 could lower the costs associated with needless follow-up exams, and improve patient experience for women seeking a more accurate screening mammogram.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release does mention that 3D mammography has been available since 2011 and includes a link to a website where people can enter their zip code to find locations that offer the additional screening test.", "answer": 1}, {"article": "This is the experience many women have.\nChanges like this can make a big difference, says Dr. William Camann, the director of obstetric anesthesiology at Brigham and Women's Hospital in Boston and one of the pioneers of the procedure in the U.S. At Brigham and Women's, their version of the family-centered cesarean is called the gentle cesarean.\nFamily-centered cesareans are a relatively new idea in the U.S., and many doctors and hospitals have no experience with them.\n\"It is the first time we have really done anything innovative or creative with changing the C-section procedure in years,\" she says.\nIn addition, Penn says, the mother's hands were not strapped down and the intravenous line was put in her nondominant hand so she could hold the baby.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This was a tricky one. The piece said family-centered cesareans are not routine, and it did not firmly establish if every mother who asks for the procedure would be accommodated. We\u2019ll give the benefit of the doubt, but we\u2019d note that the story could have addressed how women can find providers who are known to offer family-centered cesareans. It also could have discussed whether hospitals are generally willing to accommodate these practices if asked to do so.", "answer": 1}, {"article": "Dubbed Stop-af, the Medtronic trial showed that almost 70 percent of patients who had cryoablation remained free of the condition after one year, compared with just 7 percent of patients who received drug therapy, according to data presented at the American College of Cardiology meeting in Atlanta.\n\u201cThis is the best data we have at this point in support of cryoablation (to treat atrial fibrillation),\u201d said Dr. Douglas Packer of Mayo Clinic, the lead investigator of the study.\nA clinical trial of Medtronic Inc\u2019s (MDT.N) cryoablation system looked at 245 patients with paroxysmal atrial fibrillation, a condition marked by intermittent episodes of abnormal heart rhythm that causes the upper chambers of the heart to quiver.\nPatients in the pilot study had advanced atrial fibrillation and tended to have other medical problems, such as high blood pressure, diabetes or coronary artery disease,\n\nPacker, who also led the pilot study, dubbed Cabana, acknowledged that the main limitation of this study was its small size, but said it lays the foundation for a larger one.\nDamage or irritation to the nerve that controls the diaphragm was reported in 11 percent of the cryoablation procedures, but none of the cases was considered serious, with 98 percent resolved by the 12-month follow-up.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Towards the end, the story mentions that the treatment device discussed is not yet approved for use, though a device made by a different company (Johnson and Johnson) has been used to treat AF for years.", "answer": 1}, {"article": "FDA approves breakthrough cholesterol drug, but only for certain high-risk patients\n\nOvereating may be caused by a hormone deficiency, scientists say\n\nCDC report: Lyme disease is spreading to new territories\n\nResearchers retract study claiming marriages fail more often when wife falls ill\nResearchers at Sheffield University found that in postmenopausal women during the first 10 years after diagnosis of breast cancer, the drug could reduce the risk of death by 18 per cent.\nThe researchers wrote in the study that a substantial number of the trial participants switched from tamoxifen to aromatase inhibitors after they heard that it could reduce recurrence, which affected their results.\nThe study reported that \"taking aromatase inhibitors for 5 years reduced the risk of postmenopausal women with breast cancer dying of their disease by 40 percent within 10 years of starting treatment, compared with no hormonal treatment.\"\nIn a study published in The Lancet on Thursday, researchers found that a class of inexpensive, existing generic called aromatase inhibitors, which suppress hormones, reduce recurrence rates by 30 percent as compared with tamoxifen.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article describes aromatase inhibitors as \u201ca class of inexpensive, existing generics\u201d and bisphosphonates as drugs typically used to treat osteoporosis.", "answer": 1}, {"article": "\"The protection started at more than 45 grams [about 1.5 ounces] a week,\" says researcher Susanna C. Larsson, PhD, of the Karolinska Institutet in Stockholm, Sweden.\nWhile other studies have found a link between eating chocolate and reduced stroke risk, this research found a slight difference in protection, depending on type of stroke.\nThose who ate the most chocolate were protected a bit more from strokes caused by hemorrhage than strokes caused by obstruction such as blood clots.\nIn this group, the median intake (half ate more, half less) was about 2.3 ounces a week.\nOct. 10, 2011 -- A healthy chocolate habit -- about two chocolate bars a week -- appears to help women reduce their risk of stroke, according to new research.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of chocolate bars is not in question. But it is important to note that the chocolate sold in Sweden typically has a higher concentration of cocoa solids \u2014 the likely source of any protective effect \u2014 than chocolate sold in the U.S. The story makes this clear.", "answer": 1}, {"article": "Researchers have found strong evidence that adenotonsillectomy \u2014 the surgery to remove the tonsils and adenoids \u2014 can help relieve childhood behavioral or attention problems, including attention-deficit hyperactivity disorder, or A.D.H.D.\nResearchers studied 78 children who were scheduled for the operation, and a control group of 27 children having other surgery.\nThe rest have the operation to relieve breathing difficulty or nighttime sleep apnea, a serious disorder in which the sleeping child briefly stops breathing during the night.\nAlthough the surgery has become less common with antibiotics, more than 400,000 children under 15 have their tonsils, adenoids or both removed every year, according to estimates by the Metropolitan Insurance Company.\nAll the children spent one night in a sleep laboratory to record their sleep and breathing patterns.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that adenotonsillectomy is a common surgery in the U.S.", "answer": 1}, {"article": "(Reporting by Susan Kelly, editing by Dave Zimmerman)\n\u201cWhat we\u2019ve been able to show is that by combining this technology, you can lower the A1C, which reduces your risk of complications, and you can do it safely without increasing your rate of hypoglycemia,\u201d said study author Dr. Richard Bergenstal, executive director of the International Diabetes Center at Park Nicollet Health Services in Minneapolis.\nIn the study, patients on pump therapy saw a reduction in average A1C levels of 0.8 percent, compared with a 0.2 percent average reduction for those who received multiple injections.\nAdult and pediatric patients using the pump and continuous glucose monitoring device saw reductions in levels of A1C, a commonly used measure of blood sugar, that were four times greater than those who received regular insulin injections in the study of 485 patients ranging from age 7 to 70.\nPatients in the study, which was presented at a meeting of the American Diabetes Association in Orlando, Florida, and sponsored by Medtronic, achieved better glucose control over a one-year period without an increase in hypoglycemia, or dangerously low blood sugar.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>\n\n\n\n \nThe story points out that these results are from a post-market study, thus indicating the device is already available. However, an editorial in the New England Journal of Medicine accompanying the research article made an important point that was not included in the study: devices are not enough, effective glucose management requires effective management\u2026 and the \u201cexpert training and guidance received by patients in clinical trials cannot be readily duplicated in a busy clinical practice.\u201d In other words, the results of this trial may not necessarily be achieved in general clinical practice because while the devices tested are widely available, expert support services are not.\n", "answer": 1}, {"article": "Lakhan tells WebMD in an email that the extracts were administered orally.\nThe reviewed studies included the use of cannabis extracts delta9-tetrahydrocannabinol, or THC, and cannabidiol, or CBD, in people with MS.\n\n\"We found evidence that combined THC and CBD extracts may provide therapeutic benefit for MS spasticity symptoms,\" Lakhan says in a news release.\nIn the paper, published in the open access journal BMC Neurology, the researchers write that recently introduced therapies of combined THC and CBD have the potential to relieve symptoms and that past reviews have suggested that cannabinoid therapy is beneficial for people with MS.\n\nGenerally, use of the marijuana extracts were well-tolerated in patients, the researchers write.\nThe reviewed studies were published between 2002 and 2007 and included data from nearly 500 people with MS. Five of the six studies analyzed reported significant improvements in spasticity; one study reported no improvement in spasticity.\nThe review, by Shaheen Lakhan, PhD, and Marie Rowland, PhD, of the Global Neuroscience Initiative Foundation in Los Angeles, found that five of six published studies they analyzed reported a reduction in spasticity and an improvement in mobility in MS patients treated with marijuana extracts.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described \"marijuana extracts\" but never clarified whether they were now available or still experimental.\u00a0 Also, many people would want to know how these extracts \u2013 taken by mouth \u2013 differ from smoking marijuana \u2013 which the story never explained. ", "answer": 0}, {"article": "Carissa Cascio, an assistant professor of psychiatry from Vanderbilt University School of Medicine, who specializes in autism and neuro-imaging, believes these study results are important.\nWhile previous studies using different types of scans have been able to identify people with autism, Lange says, \"no one has looked at it [the brain] the way we have and no one has gotten these type of results.\"\nBut she cautions that using this method as a true diagnostic tool to detect autism in a child is \"a long way off.\"\n(The advocacy group Autism Speaks has posted videos to help parents see the signs of autism)\n\nThe earlier a child has been identified as having autism, the earlier behavioral therapies can be applied to lessen the impact of the disorder later in life.\nZachary Warren, who is the director of the Vanderbilt Kennedy Center Treatment and Research Institute for Autism Spectrum Disorders (TRIAD), says since there are many types of autism, \"it becomes very challenging to capture all these differences with one test.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does a better job than the Reuters story of showing that these scans will not be rolling into your local mall anytime soon. \u201cLange is quick to caution that this type of test is not yet ready for prime time. \u201cWe do not want to give anyone false hopes that this is ready for the clinic yet. This method, this test, needs to be tried [and confirmed] with many more subjects outside our laboratory,\u201d he says.\u201d", "answer": 1}, {"article": "A protein present on tiny particles released by cancer cells may provide a way to detect pancreatic cancer in its earliest stage, when prospects for successful treatement are best, according to a study by researchers at the University of Texas M.D.\nThe researchers found that the presence of the protein could distinguish with 100 percent accuracy whether patients had early stage pancreatic cancer or chronic pancreatitis, a major risk factor for the cancer.\nThe pancreas is located deep within the body, so early tumors cannot be seen or felt during routine physical exams.\nIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer.\n\"This presents an unprecedented opportunity for informative early detection of pancreatic cancer and in designing potential curative surgical options.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article is clear that the test is not yet available. In reporting on the finding, the story states that \u201cIf such a test were developed, it would likely be used first to test patients at high risk for pancreatic cancer\u201d and adds that it still needs to be shown that the screening would improve outcomes for patients with pancreatic cancer. The story contains a lot of conjecture for a test not yet developed.", "answer": 1}, {"article": "When considering where to give birth, most parents-to-be and doctors in Western nations believe a hospital is the best place.\n\nNot so Jean Stevens, 32, who chose to deliver two children at home in the U.K. She says her two labors were nearly pain-free.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is another close one. The story does explain the difference between hospitals and birth centers, but doesn\u2019t let readers know how common birth centers are in the U.S. Nor does it mention the availability of midwife services for home births, which can vary by state. However, the story does cite one U.S.obstetrics expert as saying that more birth centers could be established. Because the story addressed the issue, at least tangentially, we\u2019ll give it the benefit of the doubt.", "answer": 1}, {"article": "\"In Europe, we have been reluctant to recommend that all men get PSA testing as we have felt that there has been a lack of knowledge,\" agreed lead researcher Dr. Jonas Hugosson, a professor of urology at the University of Gothenburg.\n\"When we see patients with low-risk disease we don't treat them, we observe them,\" he said.\nThe report is published in the June 30 online edition of The Lancet Oncology.\nThe men were between 50 and 65 at the start of the study.\nIn addition, men in the screened group were more likely to have their cancer diagnosed while it was in an early stage.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story accurately reported the widespread use of the PSA test to screen for prostate cancer in the U.S.", "answer": 1}, {"article": "But then a few years later she started noticing something interesting.\n\"There hasn't been much action in this area, and that certainly has to come up when a company is thinking about dumping money into researching a drug for female sexual dysfunction,\" says Phyllis Greenberger, president of the Society for Women's Health Research, which received money from Boehringer Ingelheim, the company that makes flibanserin.\nYou can find a practitioner through the National Certification Commission for Acupuncture and Oriental Medicine, or if you prefer a medical doctor, visit the website of the American College for Advancement in Medicine, where you can put in your ZIP code and find a doctor who specializes in integrative medicine.\nIn 2008, a survey of more than 30,000 U.S. women in the journal Obstetrics & Gynecology found that nearly 40 percent reported that they'd had a sexual problem at some point in their lives, most often a lack of desire.\nHere's more information on ginkgo, including its sexual effects, from the National Center for Complementary and Alternative Medicine at the National Institutes of Health.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes that an FDA panel voted against approval of flibanserin, an investigational drug for treatment of low sexual desire in women.\u00a0The availability of the alternative libido-boosting therapies discussed in the article isn\u2019t really in question, but the story does provide links to organizations which maintain lists of alternative health providers. \u00a0", "answer": 1}, {"article": "The study was was paid for by Cytograft Tissue Engineering.\nThe vessels failed in three of the patients, which experts said was not surprising in patients so seriously ill. One other patient withdrew from the study and another died of unrelated causes.\n\"It's difficult to predict what will happen next, but they are on the right track,\" Mironov said.\n\"This technology is very, very promising,\" said Vladimir Mironov of the Medical University of South Carolina, who co-wrote an accompanying commentary in the Lancet that praised the study as \"a revolutionary milestone.\"\nBut because dialysis is done so regularly, kidney patients often run out of healthy vessels and need an artificial one, often made out of gortex.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that the tissue-engineered blood vessel grafts are still experimental. It says only that this sort of lab-grown blood might help patients \"one day,\" without predicting success within a specific time period.", "answer": 1}, {"article": "It\u2019s a single.\u201d\n\nSaying that even a single was helpful, Dr. Kahl was part of a majority on the panel that recommended approval of the drug, 10 to 4.\nIt says it will give the drug free to uninsured patients who cannot pay for it any other way.\nIn the clinical trial, the median duration of use was 70 days, which would cost roughly $70,000 to $80,000.\nSo the total cost of using Folotyn will be less than for many other drugs with lower monthly prices.\n\u201cEvery dime that goes into the company supports Folotyn,\u201d Mr. Caruso said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that Folotyn is not currently available but that the manufacturer plans to market the drug in January.", "answer": 1}, {"article": "The report concluded that both are necessary for bone health but that as for preventing cancer, heart disease, diabetes and autoiummune disorders, the evidence was \u201cinconsistent, inconclusive as to causality, and insufficient to inform nutritional requirements.\u201d Even so, the committee recommended that children and adults up to age 70 get 600 IU of vitamin D daily \u2014 from food and, if necessary, supplements \u2014 and that adults age 71 and older get 800 IU.\nAt the end of the studies, one of us will be right.\n\u201cPeople want to have a simple story they can believe in,\u201d he says.\nThat\u2019s why there are no official recommendations yet from any medical organizations.\n\u201cIt\u2019s fine to take that amount,\u201d Manson said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that vitamin D is widely available from food and supplements.", "answer": 1}, {"article": "Franks says thalidomide can help an additional 75% of patients achieve remission.\nThe researchers note that the study dose was \u201cgenerally well-tolerated.\u201d No new nerve symptoms were reported.\nThe majority of the patients (60%) had the most common subtype of lupus-related skin disease, known as discoid lupus erythematosus, which is characterized by red, scaly patches that can scar.\nThe lenalidomide study included 15 women with lupus skin conditions; six had lupus in other areas of the body, too.\nIn more recent years it has been brought back to the market to treat a number of serious conditions, but its use is monitored closely to ensure that it is not taken by women who are pregnant or who might become pregnant.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that \u201d Lenalidomide is available as Revlimid to treat people with multiple myeloma and myelodysplastic syndromes.\u201d\u00a0 But for the lupus skin conditions in question, it is unclear if some doctors were currently using it off-label.\u00a0 We think the story should have discussed this.\u00a0 Any of the doctors interviewed could have answered this.", "answer": 0}, {"article": "This posed a conundrum.\nBut the downsides to getting a vaccine are extremely minimal, and flu shots may still be helpful in reducing some illness and saving lives, which is why public health experts say you should get vaccinated anyway.\nIn kids, the highest-quality evidence \u2014 a randomized controlled trial \u2014 suggests the vaccine works well enough: On average, if you give six kids under the age of 6 a flu shot, you can expect to prevent one case of the flu.\nAs Roger Baxter, the co-director of the Kaiser Permanente Vaccine Study Center, told me, \"Flu vaccines are not a panacea, and do not prevent all cases of flu, even in the best years, when there are no manufacturing problems and the match is perfect.\"\nIn a good year, when the WHO guesses correctly and the flu shot matches the strains in circulation, you need to give 33 adults flu shots, on average, to prevent one case of illness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers answers to basic questions about the value of getting an annual flu shot.\u00a0 Those questions are obviously based on the fact that flu vaccines are usually readily available for those who want them.\u00a0 While some years present a possible shortage of vaccine, for most years, vaccination is determined by personal choice, rather than availability.", "answer": 1}, {"article": "MORE: Losing Focus?\nIn the past, these benefits have been hard to test scientifically, largely because study participants who volunteered for meditation programs may have been biased to see them succeed.\nMORE: Medical Meditation: Say Om Before Surgery\n\nAfter roughly five years of follow-up, the researchers found a 48% reduction in the overall risk of heart attack, stroke, and death from any cause among members of the meditation group compared to those from the health education group.\nBut while the magnitude of those results is remarkable, the study involved a relatively small number of participants, and did not reveal how meditation may be lowering heart disease risk.\nMost doctors say meditation can't hurt you, but now there's reassuring evidence that it may help you as well when it comes to warding off disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Questions like the availability of meditation trainers, insurance coverage, and the acceptability/willingness of\u00a0most patients to commit to\u00a0meditation therapy over the long-term are not addressed.", "answer": 0}, {"article": "The best performers included amitriptyline and escitalopram, while the worst included fluoxetine\u2014commonly sold under the trade name Prozac\u2014and reboxetine, which is not approved for sale in the U.S.\nIn many countries, the rate drops to less than 10 percent.\nWhile these results should reassure many people with depression that antidepressants can be effective, \u201cthis does not necessarily mean antidepressants should always be the first line of treatment,\u201d he said.\nExperts not involved in the research agreed the results were significant.\nAntidepressant drugs really do work, a major new international study has proven.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "A wide range of antidepressant medications have been on the market for decades, so there\u2019s no need to mention availability.", "answer": 2}, {"article": "But if you prefer something less invasive but more frequent, you can test your poop every year without feeling like you\u2019re opting for, um, No.\nThe United States Preventive Services Task Force says the net benefit for screening adults age 50-75 is \u201csubstantial,\u201d adding that colorectal cancer is the second-leading cause of cancer death in the country.\nIncluded on the list are two cheap, at-home poop tests intended to be done annually: the guaiac-based fecal occult blood test (gFOBT) and a more sensitive test called the fecal immunochemical test, or FIT.\n\u201cThey were very clear: We\u2019re going to stick to the evidence, and right now we don\u2019t have evidence for colonoscopy,\u201d said Aasma Shaukat, section chief of gastroenterology in the Minneapolis VA Health Care System.\nThere is indirect evidence it reduces colorectal cancer deaths, in the form of a large study following people who did and didn\u2019t get the test over time.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both colonoscopy and sigmoidoscopy have been available for years and the at-home screening tests mentioned in the story are said to be available through a patient\u2019s doctor\u2019s office. These details establish the methods\u2019 availability.\u00a0 It also quotes one source as\u00a0recommending against\u00a0the use of over-the-counter home screening tests for this disease.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\nOne in eight women in the United States will develop breast cancer at some point during their life.\nThe most common exam offered for asymptomatic patients seeking supplemental screening is a whole breast screening ultrasound examination.\nHowever, screening ultrasound examinations have higher rates of false positives, meaning more cases of positive screenings where no cancer is present.\nBased on the preliminary results at Penn Medicine, the cancer detection rate of AB-MR screening is 25 cancers per 1,000 patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There was no mention of the availability of abbreviated breast MRI.", "answer": 0}, {"article": "It depends on the time of year.\n\u201cAlmost certainly, I would be deceased or in much worse shape had I not had the opportunity to be in this program.\u201d\n\nHare stressed that the current trial is only a small, run-up phase of extensive testing that will take up to five years and involve dozens of hospitals and hundreds of patients before winning U.S. Food and Drug Administration approval for routine use.\nMax Eaton, the 68-year-old direct-buy franchise owner who was patient No.1 in the eight-person trial, said Wednesday he's thankful he was part of the trial, adding that he had just completed a 2.8-mile, 41-minute walk around his neighborhood in Lauderdale-by-the-Sea, Fla.\n\n\u201cI feel very grateful,\u201d he said.\nThe first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works.\n\u201cThat's the Holy Grail, the quest the whole field has been pursuing for close to a decade, and this is evidence we're on the right track,\u201d said Dr. Joshua Hare, director of the University of Miami Medical School's Interdisciplinary Stem Cell Institute.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This story stands out for taking readers through the application and approval process instead of just leading readers to believe that a therapy is around the corner. It says: \u201cThe next step is two more near-term studies. The first, which started in 2009, is a double-blind, placebo-controlled study of 60 patients designed further to test the safety of the procedure, but primarily its efficacy, or how well it works. Another study about to get underway will see whether bone marrow from a donor can work as well as the patient\u2019s own bone marrow. Later, researchers will conduct a study involving 50 to 100 hospitals and many hundreds of patients aimed at winning final FDA approval.\u201d\n", "answer": 1}, {"article": "(Editing by Jon Loades-Carter)\nBapineuzumab \u2014 being developed by Pfizer Inc (PFE.N), Irish drugmaker Elan Corp ELN.I and Johnson & Johnson (JNJ.N) \u2014 is a potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\n\u201cIt demonstrated that the drug has an effect on the pathological hallmark of Alzheimer\u2019s disease,\u201d lead researcher Juha Rinne from Finland\u2019s University of Turku told Reuters.\nCommenting on the results, Sam Gandy from New York\u2019s Mount Sinai School of Medicine said it was too early to say effective disease-modifying drugs were at hand, but the ability to measure plaque in living subjects was \u201csomething of a breakthrough\u201d.\n* Drug being developed by Pfizer, Elan and Johnson & Johnson\n\nLONDON, March 1 (Reuters) - New imaging technology suggests an experimental drug for Alzheimer\u2019s reduces clumps of plaque in the brain by around 25 percent, lifting hopes for a medicine that disappointed in clinical tests two years ago.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Bapineuzumab, the drug reported on, is experimental and not available for use outside of clinical trials. \u00a0The story mentioned the experimental status once, but the fact that it is not available was probably lost on many readers who may have been swept away by the enthusiastic reporting: \"potential game-changer because it could be the first drug to treat the underlying cause of the degenerative brain disease.\"", "answer": 0}, {"article": "The study received no funding from private industry.\n\"Of course, it remains to be seen if the demonstrated benefit already seen holds up over a longer period of time, and with a bigger group of patients.\"\nSUNDAY, March 1, 2015 (HealthDay News) -- A procedure that delivers the anesthetic lidocaine (Xylocaine) directly to nerves in the back of the nasal cavity appears to offer significant relief to migraine sufferers, preliminary research indicates.\nThe day after the procedure, average migraine pain levels had dropped from about 8 to just over 4.\nAnd, he said, the hope was that lidocaine would essentially short-circuit that bundle's headache-causing pathway.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of lidocaine (Xylocaine) was not in question, as the drug has been synthesized since the 1940s. It is now widely available in pharmacies. The bigger issue would be finding a specialist every month to deliver these infusions. Is it a procedure that any interventional radiologist could perform? Would they need any special training? The story doesn\u2019t establish whether one can request this procedure right now or if it\u2019s something headache sufferers will need to wait for.", "answer": 0}, {"article": "A recent study has found evidence suggesting text messages could reduce one\u2019s odds of a second heart attack.\n\nA six-month clinical trial in Australia found that patients recovering from a heart attack were more likely to maintain lower blood pressure, less body fat and lower cholesterol levels than a control group when the patients received text messages asking and giving suggestions about their health routines. Patients receiving the texts also were more likely to be active and to quit smoking than the patients in the control...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the study leader is now involved in an effort to replicate her results, which implies that the treatment regimen is not available at present. However, studies of social media and apps used to promote healthy behaviors\u00a0are ubiquitous, so\u00a0it might\u00a0have been useful for the reporter to explore the availability of this strategy compared to others on the market now.", "answer": 1}, {"article": "So, the investigators asked, could a scan identify those whose actual risk is lower than what was calculated?\nAccording to today\u2019s guidelines, half had risk scores high enough that a statin would be recommended or should be considered.\nBut the amount of calcium in arteries can give a good idea of the presence or extent of coronary artery disease.\nThe study subjects were nearly 4,000 men and women ages 45 to 84 and included blacks, whites, Hispanics and Asians who were recruited in 2000 through 2002.\nThe hard plaques are not the dangerous ones \u2014 it is the softer ones that rupture and cause a heart attack.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that this test is readily available, and points out that it is generally not covered by insurance.", "answer": 1}, {"article": "Led by John Weeks (johnweeks-integrator.com), the Co-founder and past Executive Director of the Academic Collaborative for Integrative Health, JACM publishes controlled trials, observational studies, scientific reviews and leading commentary intended to help medical organizations and governmental organizations optimize the use of integrative products, practices, and practitioners in patient care and in delivery and payment strategies.\nThe study design and results, which suggest further controlled studies of this intervention approach in ASD, are published in the Journal of Alternative and Complementary Medicine (JACM), a peer-reviewed publication from Mary Ann Liebert, Inc., publishers.\nIts biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide.\nA complete list of the firm's more than 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.\nThe researchers measured the effects of the intervention on factors such as the children's behavior, ability to pay attention, sleep, and aspects of parenting stress.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability at all. While many (or most) readers are aware that acupuncture therapy exists, they may be less familiar with how widely available it is. Readers may not be aware of pediatric acupuncture at all, much less pediatric acupuncture for children with ASD. Is there a special certification for pediatric acupuncture therapy? What about for pediatric ASD acupuncture therapy? The release doesn\u2019t tell us.", "answer": 0}, {"article": "\"Despite poorer performance compared with women without a prior history of breast cancer, overall screening mammography was effective at detecting the majority of breast cancer in women with a [history] at an early favorable stage, with the majority of tumors being diagnosed as ductal carcinoma in situ or stage 1,\" Smith said.\nThe interval cancer rate was 3.6 per 1,000 screenings in those with a history and 1.4 per 1,000 in those without, the investigators found.\nIt points to the need, she said, for women to remain vigilant about screening after their breast cancer treatment -- and to report any symptoms to their doctor immediately.\nFor those who have dense breasts and are younger than 50, for example, \"we can alternate mammograms with breast MRIs,\" with one of the tests every six months, he said.\nAfter surgery and radiation, he said, a woman's breasts have changed, and there is a greater chance that a radiologist will think that something is abnormal simply because of the changes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 Mammography is widely available and recommendations for annual mammography screening after a breast cancer diagnosis are standard. So the story didn\u2019t need to specifically discuss the availability.", "answer": 2}, {"article": "This data is clinically significant.\n\"For certain patients, treatment options for migraines, such as oral medications, are not effective, well-tolerated or preferred,\" Dr. Starling adds.\nMigraine symptoms, which can be debilitating for many people, are the sixth leading cause of disability, according to the World Health Organization.\n\"The sTMS may be a great option for these patients and allow doctors to better meet their unique needs.\"\nMULTIMEDIA ALERT: Video and audio are avaiable for download on the Mayo Clinic News Network.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that the subjects in this study self-administered \u201cpulses\u201d each morning and evening, but readers are left wondering if this is done at a medical center or at home. If the former, do most hospitals and clinics have TMS machines? If done at home, how and where does one get a machine? Unclear.", "answer": 0}, {"article": "Carlson notes that many cognitive intervention studies last one year or less.\nOne strength of this study, she says, is that the participants were followed for two years, which in this case was long enough to see changes that wouldn't have been detected after just one year.\nThe researchers were particularly interested in the results, considering that people with less education and who live in poverty are at greater risk for cognitive decline.\nThe brain shrinks as part of aging, but with this program we appear to have stopped that shrinkage and are reversing part of the aging process.\"\nAt the same time, those with larger increases in the brain's volume over two years also saw the greatest improvements on memory tests, showing a direct correlation between brain volume and the reversal of a type of cognitive decline linked to increased risk for Alzheimer's disease.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We don\u2019t believe that the availability of volunteering is an issue, but the story does note that this particular program \u2014 the Experience Corps \u2014 isn\u2019t available everywhere.", "answer": 1}, {"article": "The patient blows a single breath into a specialized balloon.\nDr. Schumer said those grim statistics underscore the need for early detection, \u201cWe hope that breath analysis will allow us to diagnose patients with primary or recurrent lung cancer long before they suffer from symptoms, when we have more options for treating them, giving them the best chance for cure.\u201d\n\nCurrently, lung cancer patients are followed after surgery with chest computed tomography (CT) scans, which can be inconvenient, expensive, and expose the patient to radiation.\nOur next step is getting approval from the FDA.\u201d\n\nNote: This work was supported by the Coulter Foundation, V Foundation, National Science Foundation, and Bill and Melinda Gates Foundation.\nBousamra, van Berkel, and Fu disclose a financial relationship with Breath Diagnostics, Inc.\n\nFor a copy of The Annals article, contact Jennifer Bagley at 312-202-5865 or jbagley@sts.org.\nThe researchers found a significant decrease in overall carbonyl VOC levels following surgery; in fact, three of the four carbonyl VOCs normalized after surgery, matching levels in the control group.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Early on the release states, \u201cNow the test is being used to monitor for disease recurrence.\u201d That sentence might confuse some readers into thinking the test is already in use. You have to read to the end to learn from a researcher\u2019s quote that \u201cOur next step is getting approval from the FDA.\u201d So that\u2019s a signal to readers that the test is not yet available, and may not be for some time. In addition, the comment about FDA approval doesn\u2019t give us any sense of the hurdles/obstacles that remain before the test would be validated for clinical use.", "answer": 0}, {"article": "To learn more about DOs and the osteopathic approach to medicine, visit http://www.\nWe also know that many people tune out messages about nutrition and exercise until a health crisis gets their attention,\" said Jennifer Caudle, DO, assistant professor of family medicine at Rowan University.\n\"There are significant benefits to early disease detection because we now know that many of the same conditions that lead to vascular disease are also significant risk factors for Alzheimer's.\nIn Alzheimer's, the brain begins to change years before symptoms emerge.\nIt is among the top 10 causes of death in America.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "What does \u201cclosing in on a blood test\u201d mean?\nWhat does \u201cnearing development of a blood test\u201d mean?\nDoes it mean a month? A year? A decade?\nAnd on what basis are these crystal ball predictions made?", "answer": 0}, {"article": "Handedness (molecular asymmetry) is critical to the function of bio-molecules in the body.\nThe same can be true of molecules, and in some cases, having the wrong handed molecule can have profound biological consequences.\nIn this case, the osmium compound JPC11, with sodium formate, can selectively produce a molecule of a specific 'handedness' - thus manipulating how cancer cells grow.\nProfessor Martin Wills, catalyst specialist at the University of Warwick, commented:\n\n\"Although asymmetric catalytic hydrogenation processes are well developed in the materials industry, this research provides the first ever example of it being achieved inside cells using a synthetic catalyst.\"\nProfessor Peter Sadler, a medicinal chemist at the University of Warwick commented:\n\n\"Platinum compounds are the most widely used drugs for cancer chemotherapy, but we urgently need to respond to the challenges of circumventing resistance and side-effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "At the beginning of the 14th paragraph, the release notes that \u201cIt will take time [for JPC11] to progress from the lab to the clinic.\u201d Those are the only words that tell readers anything about where JPC11 is in the development process. The release does not tell readers what has been accomplished (some in vitro testing), what is next, what hurdles lie beyond that, or anything else pertaining to how long it may take for this to develop into a useful clinical tool. And there is no acknowledgment that it may never become a practical treatment.", "answer": 0}, {"article": "Probabilities may not grab all patients by the collar. But telling someone he or she has a better than 1-in-3 chance of dying before the next decade's out (or even a better than 1-in-10 chance) would probably be a sobering reminder to hit the gym. The authors said the metric \"can be used to communicate fitness-related risk and motivate behavioral change after exercise stress testing.\"", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We have mixed feelings about this one. On the one hand, the story says, \u201cDo-it-yourself stress testing is probably not very reliable, since a physician or sports physiologist needs to be around to decide when to call a halt to the test (and therefore what maximum a test-taker has achieved).\u201d But then it encourages people to try to develop their own score at the gym or at home and gives them the formula that the researchers used. It\u2019s great to give readers all the information, but we would have preferred that the story emphasize that the validity of the results stems from how these tests were conducted in a clinical setting.", "answer": 1}, {"article": "June 30, 2010 -- A drug used in Europe as emergency contraception may also treat painful uterine fibroids, researchers say.\nThe new drug is manufactured by HRA Pharma, a European pharmaceutical company, which provided funding for the new study.\nThe hormone progesterone also feeds uterine fibroids, so blocking its effects may help treat painful fibroids.\nIt is effective for up to five days after unprotected sex.\nAs many as 80% of all women have uterine fibroids (noncancerous growths in the uterus), according to the nonprofit National Uterine Fibroids Foundation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that EllaOne is available for emergency contraception only in Europe but is being considered for approval in the US.", "answer": 1}, {"article": "The study examined associations between pasta consumption, shortfall nutrient intakes as defined by the 2015 Dietary Guidelines (2015 DG) and diet quality in comparison to non-pasta consumption in U.S. children and adolescents (ages 2-18).\nPasta pleases even the pickiest of young eaters.\nNPA is the leading trade association for the U.S. pasta industry.\n\"Good nutrition is critical to the developing minds and bodies of children and adolescents.\nThe data review did not look at any health outcomes associated with pasta consumption except for the ones specified below.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "We\u2019ll rate this Not Applicable since it is generally known that pasta is inexpensive and widely available.", "answer": 2}, {"article": "Viagra is one of three licensed drugs to treat erectile dysfunction, Davies explained. The other two are Cialis and Levitra. They can take from half an hour to several hours to work, and they're not for everyone: Men who've had a stroke or heart attack are told to use the drugs with caution, reports the Daily Mail. Even those without medical issues simply don't like the wait.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story stated that \"the new cream may not be widely available for 10 years,\" but that didn\u2019t stop them from writing about it or touting its \"promise.\" ", "answer": 1}, {"article": "\"CCSVI equals hope and a lot of MS patients just are completely devoid of hope,\" Stecker says.\nHowever, Zamboni suggests that the disease instead is the result of blocked blood veins \u2014 leading to inflammation, which, in turn, causes the immune system to attack nerves in the brain and spinal cord.\n\"Even if the treatment is not useful for patients with MS, I don't think that we can abandon the idea of vascular involvement in MS,\" Zivadinov says.\nThese discrepancies, and growing public controversy, prompted the National Multiple Sclerosis Society in the U.S. and the Multiple Sclerosis Society of Canada to take Zamboni's claims seriously.\nIt's so seductive, in fact, that Canadians and Americans with MS have been flocking overseas to get the \"liberation procedure.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article implies that there aren\u2019t yet a lot of doctors performing this\u00a0procedure, but it isn\u2019t clear.\u00a0Early in the story we learn of\u00a0a patient\u00a0who recently had the procedure performed in New York, but later on\u00a0the story\u00a0says that Canadians and\u00a0Americans\u00a0are going to Europe\u00a0to have\u00a0the surgery.\u00a0Are there not enough doctors\u00a0in North America who are trained to perform this procedure? Or are there regulatory, legal, or financial\u00a0issues that are preventing patients in North\u00a0America from getting\u00a0it done here? \u00a0The story should have told us.", "answer": 0}, {"article": "Despite all the headlines about swine flu, which has become the main influenza strain circulating in the world, doctors do expect some garden-variety flu to hit this fall too \u2013 the kind that every year kills 36,000 Americans and hospitalizes 200,000.\nThe report from the Centers for Disease Control and Prevention Friday also came with good news: Testing of vaccines for swine flu show that they work with a single dose and take effect rapidly.\nHealth officials say influenza is circulating unusually early this year with cases in every state \u2013 and nearly all the infections are swine flu.\nThe highest concentrations of flu cases are in the Southeast and a few other states.\nOn Friday, the NIH is set to release results of its own studies of hundreds of adults that confirm that one shot works, Fauci said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story reports that H1N1 vaccinations are expected to be available in mid-October and that seasonal flu shots are available now.", "answer": 1}, {"article": "MONDAY, March 16, 2015 (HealthDay News) -- A new study calls into question the value of removing blood clots from a patient's heart arteries during angioplasty, a procedure to open blocked arteries.\n\"These findings will likely have important implications for clinical practice,\" Fonarow said.\nAmong all the patients, 6.9 percent who had clots removed, and 7 percent of those who didn't, died, had another heart attack or developed heart failure in the 180 days after the procedure.\n\"This is an unexpected finding, and we want to confirm this in other studies,\" Jolly said.\nIt needs to be tested in large trials,\" he said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention the availability of either of these procedures, but assumes that both are readily available and widespread. That\u2019s accurate.", "answer": 1}, {"article": "Some of the complaints related to the placement of the device.\nBut since its approval in 2002, women using the device have sent the FDA more than 5,000 complaints, ranging from pain and menstrual problems to pregnancies and even deaths.\nEssure is a small metal coil inserted into woman\u2019s fallopian tubes.\nThis test is an alternative to the generally-prescribed modified hysterosalpingogram (HSG) test in which an x-ray of the uterus and fallopian tubes is used to check for proper device placement.\nThe training will start in September, the same month the FDA will hold a public panel meeting to discuss the safety and effectiveness of Essure.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "TVU is an established imaging technique and procedure, carried out by both ob-gyns and by radiologists (and in some cases ultrasound technicians). The requirement for additional training and certification is a bit curious. But since one can gather from the story that the procedure is widely available, we\u2019ll award a Satisfactory rating here.", "answer": 1}, {"article": "Research has shown that giving statins to patients who already have Alzheimer's does not seem to help.\nThose who were taking a cholesterol-lowering statin such as Lipitor, had a surprising result.\nThey were about half as likely to develop either early signs of trouble thinking or full-blown dementia.\n\"But statins as prevention for Alzheimers is not indicated at this time.\"\n\"... obesity, smoking, certain types of genetic predisposition,\" Devi said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of statins is not in question. ", "answer": 2}, {"article": "But, lead author Dr. Giacomo Koch said, \u201cWhat we found is that the improvement was more marked in those patients that were more impaired.\u201d\n\nKoch, from the Santa Lucia Foundation in Rome, told Reuters Health he thinks those patients with more severe problems would likely see a benefit outside of just test results.\nThe \u201creal\u201d magnetic stimulation group improved by about 16 percent right after the treatment and 23 percent at the later time point, while there was no significant benefit seen in patients given the fake stimulation.\nBefore treatment, right after and another two weeks later, stroke patients were given tests to measure their visual-spatial skills, as well as attention and concentration.\nHe added that the treatment isn\u2019t painful, and only takes a few minutes for each session.\nNine people in each group completed all the treatment sessions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201c\u2026brain stimulation is still an experimental technique, and not ready to be used as part of normal stroke rehabilitation.\u201d", "answer": 1}, {"article": "When left untreated, however, B.P.H.\nSurprisingly, his case is not unique.\u201d\n\nMany doctors are now urging men to become proactive earlier to prevent chronic problems in the future.\n\u201cMy father used to be up 10 times a night and said it wasn\u2019t a problem for him,\u201d said Dr. Franklin C. Lowe, professor of urology at Columbia University College of Physicians and Surgeons.\nBut for patients who have trouble getting back to sleep, \u201cthere are many effective options, and patients almost always end up with less bothersome symptoms once they choose to do something,\u201d he said.\n\u201cThere is a big difference between having the symptoms and being bothered by the symptoms,\u201d said Dr. Kevin T. McVary, professor of urology at the Feinberg School of Medicine at Northwestern University.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story listed a number approaches to dealing with benign prostatic hyperplastia, including watchful waiting, medical therapy, minimally invasive procedures, surgery as well as experimental treatment involving botox. \u00a0The story was clear that the use of botox in this context is something under investigation and not something that is in current use. \u00a0The discussion of the other approaches indicated that they are available to men interested in treatment.", "answer": 1}, {"article": "Higher soy intake was also associated with less reported fatigue.\nWASHINGTON -- Consuming soy foods (such as soy milk, tofu and edamame) and cruciferous vegetables (such as cabbages, kale, collard greens, bok choy, Brussels sprouts, and broccoli) may be associated with a reduction in common side effects of breast cancer treatment in breast cancer survivors, say a team of scientists led by Georgetown Lombardi Comprehensive Cancer Center.\nThe lead author on the study, Sarah Oppeneer Nomura, PhD, of Georgetown Lombardi, said that while further research is needed in larger study populations and with more detailed dietary data, this project addresses an important gap in research on the possible role of lifestyle factors, such as dietary habits, in relation to side effects of treatments.\nWhether the reduction in symptoms accounts for longtime use of soy and cruciferous vegetables needs further investigation, says the study's senior author, Judy Huei-yu Wang, PhD, of Georgetown Lombardi's Cancer Prevention and Control Program.\nFor example, because many treatments designed to prevent breast cancer recurrence inhibit the body's production or use of estrogen, the hormone that can fuel breast cancer growth, breast cancer patients often experience hot flashes and night sweats, among other side effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s understood that soy and cruciferous vegetables are found in basically all grocery stores so we\u2019ll rate this Not Applicable.\nHowever, there needs to be more recognition that people who live in \u201cfood deserts\u201d across the country \u2014 urban areas with limited access to affordable and fresh vegetables \u2014 cannot so easily access healthy food.\u00a0", "answer": 2}, {"article": "The study of Amgen\u2019s evolocumab involved 4,465 patients with various degrees of risk, two-thirds of whom were randomly chosen to get the drug in addition to the medication they were already taking.\nAnalysts say the drugs will have billions of dollars in annual sales and will be taken by millions of people who cannot lower their cholesterol enough using statins alone or cannot tolerate statins.\nIn the studies detailed on Sunday, both drugs reduced the bad cholesterol by about 60 percent, to about 50 milligrams per deciliter from about 120 at the start of the studies.\nStill, the findings could help smooth the way for regulatory approval, wider use of the drugs by doctors and possibly reimbursement by insurers.\nAfter one year, 0.95 percent of those in the group that received the drug had suffered a heart attack, stroke or other cardiovascular problem, compared with 2.18 percent in the group that did not take the drug.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article made it clear that these drugs are in development and not approved by the US Food and Drug Administration, but that such approval could come as early as this summer.", "answer": 1}, {"article": "For more information about the symposium, visit www.thoracicsymposium.org.\n\u201cThe low rates of side effects from SBRT for this elderly population in our study indicate that these concerns should not prevent physicians from considering definitive treatment for their inoperable octogenarian and nonagenarian patients with early stage lung cancer.\u201d\n\nFindings are based on a retrospective analysis of 58 consecutive patients who received definitive lung SBRT across four academic sites within Emory between 2010 and 2015.\n\u201cElderly patients, who are otherwise doing well, should not have treatment withheld based solely on concerns about side effects and age.\u201d\n\nThe abstract, \u201cStereotactic body radiotherapy for early stage non-small cell lung cancer in patients 80 years and older: A multi-center analysis,\u201d will be presented in detail during the poster session at the 2017 Multidisciplinary Thoracic Cancers Symposium in San Francisco (full details below).\nThe advanced form of radiation therapy (RT) was well tolerated among this relatively understudied elderly population, indicating that SBRT is a viable option for patients who may otherwise be offered no curative treatment.\n\u201cWhile multiple studies and trials have established the effectiveness of SBRT for inoperable early-stage lung cancer, one of the common reasons for not giving radiation in older patients is concern about tolerating the treatment and potential side effects,\u201d said Richard J. Cassidy III, MD, lead author of the study and a resident in radiation oncology at Emory University\u2019s Winship Cancer Institute in Atlanta.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that SBRT is a common choice for early stage lung cancer patients who are not candidates for surgery. But it\u2019s not clear how widely available this treatment is. This study was done \u201cacross four academic sites within Emory between 2010 and 2015.\u201d This implies that it may be available at academic institutions, but it doesn\u2019t state anywhere whether this is widely available in other treatment settings.", "answer": 0}, {"article": "CHICAGO (Reuters) - The longest-running breast cancer screening study ever conducted has shown that regular mammograms prevent deaths from breast cancer, and the number of lives saved increases over time, an international research team said on Tuesday.\nBut the latest results from the Swedish study show the rate of false positive results was low.\nThis will help for that,\u201d Destounis said.\nNow, 29 years after the study began, the researchers found that the number of women saved from breast cancer goes up with each year of screening.\nBreast cancer is the second-leading cause of cancer death among U.S. women, after lung cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of mammograms is not in question. \u00a0\n", "answer": 2}, {"article": "Over-the-counter multivitamins typically contain 15 to 25 IU of vitamin E.\n\nThe newly-released Physicians Health Study showed an 8 percent reduction in total cancer occurrence for participants taking a multivitamin, but no benefit was seen for rates of prostate cancer, the most common cancer seen among the participants in the study.\nThe research was sponsored by the National Institutes of Health.\nThey also saw a 12 percent reduction in the risk of death from cancer, although those findings also were not statistically significant.\nThe protective effect of the daily pill was described as \u201cmodest\u201d by the trial investigators who emphasized that the primary use of vitamins was to prevent nutritional deficiencies.\nSeveral previous studies, many relying on self-reported use of specific vitamins or supplements, have generated mixed results in terms of cancer outcomes.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of multivitamins isn\u2019t an issue.", "answer": 2}, {"article": "The results are chronicled in Robison\u2019s new book, \u201cSwitched On: A Memoir of Brain Change and Emotional Awakening.\u201d\n\nIn a moving, often harrowing narrative reminiscent of \u201cAwakenings\u201d and other popular works by the late neurologist and writer Oliver Sacks, Robison writes of the transformations these sessions helped unlock, the welcome ones \u2014 and the not so welcome.\nBut his book does illustrate that the consequences can be long-lasting, and detrimental.\u201d\n\nRobison remains optimistic that as research continues, the potential benefits will outweigh the risks.\nIt didn\u2019t occur to me that most of the news out there, most of the emotion, is, if not bad, at least not all good.\n\u201cAnd what I wrote about in the book isn\u2019t 10 percent of what they\u2019re doing now.\u201d\n\n\u201cSwitched On\u201d ends in 2013.\nHe celebrates neurodiversity more generally, too, a subject he has been teaching at William & Mary College and Harvard Medical School.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is clear that transcranial magnetic stimulation is available because it is used to treat depression. It is also clear from the story that TMS\u2019s use for treating autism is still not routine or even necessarily recommended.", "answer": 1}, {"article": "We could not find the requested page.\n\nPlease visit our home page to explore our services.", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Some of the language used suggests the technology is mature, \u201cNow, researchers at The Rockefeller University have developed an automated technology that combines imaging with digital analysis and machine learning to help physicians detect melanoma at its early stages.\u201d\nIt is not until the final\u00a0paragraph that the need for further research is noted.", "answer": 0}, {"article": "WASHINGTON -- The Food and Drug Administration on Wednesday approved ImClone Systems Inc. and Bristol-Myers Squibb Co.'s Erbitux as a treatment for head and neck cancer, the agency said Wednesday.\n\nThe drug, which is designed to block proteins involved with cancer growth, was first approved in 2004 as a colon cancer treatment.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story accurately states that Erbitux has recently been approved by the FDA", "answer": 1}, {"article": "To learn more about NAMS, visit http://www.\nAlthough electro-acupuncture produced significant sleep improvements, researchers noted that sleep quality for the participants was still not as good as it should be, implying that more research is necessary to explore possible combinations of pharmacologic and nonpharmacologic treatments.\nIt is estimated that by the year 2020 there will be nearly six million breast cancer survivors in the United States.\nNocturnal hot flashes are among the most problematic because they can contribute to poor sleep.\nAlthough it is not exactly understood how acupuncture affects sleep, it has been shown to affect a number of neurotransmitters associated with sleep, such as serotonin and melatonin.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t mention where or if electro-acupuncture is available to patients who desire such treatments.", "answer": 0}, {"article": "In March, the FDA turned down Cephalon's jet-lag application and questioned how good the data supporting it really were.\nFinally, it should be said that the Drug Enforcement Administration has made Nuvigil a federally controlled substance because it has the potential for abuse and dependence.\nWell, the Food and Drug Administration.\nThe medicine is already approved to fight narcolepsy and sleepiness related to shift work.\nThe medicine has also been linked to rare but life-threatening skin rashes, including Stevens-Johnson syndrome, and carries a prominent warning about that risk.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that Nuvigil is already approved for some uses but not for jet lag.", "answer": 1}, {"article": "\"PSA can identify those at low risk of prostate cancer and once you have done that, you can remove almost 50 percent of men in the age group 55 to 74 [from undergoing biopsies],\" said study senior author Monique Roobol, an epidemiologist in the department of urology at Erasmus University Medical Center in Rotterdam.\n\"We recommend that this operation should not be done by all urologists in small community hospitals but should be focused and concentrated on high volume centers of excellence... in order to achieve best possible results for patients,\" said study author Dr. Prasanna Sooriakumaran, a visiting fellow in urology at the Weill Cornell Medical College in New York.\nFor this study, about 20,000 men aged 55 to 74 in the Rotterdam area were screened, with those having PSA scores at or above the cut-off of 3.0 sent for biopsies and additional screenings every four years.\nDutch researchers presenting the findings at the Genitourinary Cancers Symposium in Orlando, Fla., said that few men with a PSA below 3.0 ng/ml were likely to develop prostate cancer and die of the disease.\nBut the maker of Avodart (dutasteride), GlaxoSmithKline, is unlikely to apply for new approval to market the drug for what is essentially prevention, meaning it would be used off-label in this context, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story reported on three different aspects of prostate cancer testing and treatment \u2013 PSA testing, medical therapy as an adjunct to active surveillance, and data about the learning curve in the use of robots in the surgical treatment of prostate cancer.\nIf one reads between the lines, one can infer the widespread availability of all three approaches from the story.", "answer": 1}, {"article": "CHICAGO - A minimally invasive procedure in which pulses of energy from a probe are applied directly to nerve roots near the spine is safe and effective in people with acute lower back pain that has not responded to conservative treatment, according to a study being presented today at the annual meeting of the Radiological Society of North America (RSNA).\nIn some cases, the entire disk must be removed and the vertebra fused together for stability.\nAn alternative technique, CT-guided pulsed radiofrequency (pRF), applies energy through an electrode under CT guidance to the portion of the nerve responsible for sending pain signals.\n\"Of the different therapies available, pulsed radiofrequency is among the least invasive,\" Dr. Napoli said.\nThe one-year outcomes demonstrated that CT-guided pRF was superior to the injection-only strategy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not made clear for readers if this is an experimental therapy, or if it is widely available.\nThe procedure is, in fact, a refined technique of an older procedure.", "answer": 0}, {"article": "Similar research is under way to develop breathalyzer-like devices to detect lung, breast, prostate, and other cancers.\n\u201cThere is still quite a bit of work to be done.\u201d\n\nMazzone says the breath functions in the body in much the same way that the exhaust system functions in a car, and what comes out gives a sense of how things are working inside.\n\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful,\u201d he says.\nA person\u2019s breath contains a variety of chemical compounds, and it has long been recognized that certain illnesses can affect how the breath smells.\nDec. 5, 2012 -- A breath test similar to the one used to determine when a driver has had too much to drink shows promise as a screening tool for cancer .\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It always makes us nervous when a source is allowed to speculate, without reasonable justification,\u00a0about when an experimental device will be available clinically. And that\u2019s exactly what happened here\u00a0when an expert said that\u00a0a breath test for cancer \u201cmay be a reality in as little as five years if all goes well.\u201d On the other hand, the story did qualify things quickly when the expert added,\u00a0\u201cBut we are still in the research phase, and there is still the possibility that this technology will never prove clinically useful.\u201d Borderline, but we\u2019ll call it satisfactory.", "answer": 1}, {"article": "Patients were randomised to receive the combination of anti-TNF\u03b1 and anti-IFN?\nFlorence, Italy - 9 July 2016: Immunotherapy reduces cardiovascular risk in patients with rheumatoid arthritis, according to research presented today at Frontiers in CardioVascular Biology (FCVB) 2016 by Professor Aida Babaeva, head of the Department of Internal Medicine, Volgograd State Medical University, Volgograd, Russia.1 The combination of two extra-low dose anticytokine drugs reduced rheumatoid arthritis disease activity and cardiovascular events.\nThe incidence of cardiovascular events (unstable angina, severe hypertensive crisis, and deterioration of chronic heart failure) was more than double in the group on conventional disease-modifying drugs alone (37%) compared to those also taking the combination of anticytokines (13%).\nIn patients with highly active disease, the standard biologics are better at preventing severe complications such as progressive joint destruction and/or systemic manifestations (vasculitis, uveitis, involvement of internal organs).\nFor example, rheumatoid arthritis is associated with dysfunction of the blood vessel lining (called endothelium), which leads to lipid accumulation in the artery wall, plaque formation and atherosclerosis.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It can be safely assumed that the biologics mentioned in the study are on the market, but are the \u201cextra-low dose combination of two anticytokines\u201d readily available? We\u2019re not sure.", "answer": 0}, {"article": "The Cochrane reviewers selected 15 studies that enrolled a combined 1,360 participants.\n\u201cBut there still needs to be consensus about the dose.\u201d\n\nZinc experts say that many over-the-counter zinc products may not be as effective as those studied by researchers because commercial lozenges and syrups often are made with different formulations of zinc and various flavors and binders that can alter the effectiveness of the treatment.\nWhen taken within 24 hours of the first runny nose or sore throat, zinc lozenges, tablets or syrups can cut colds short by an average of a day or more and sharply reduce the severity of symptoms, according to the Cochrane Database of Systematic Reviews, a respected medical clearinghouse.\nWhile it\u2019s not certain how the mineral curbs colds, it appears to have antiviral properties that prevent the cold virus from replicating or attaching to nasal membranes.\nA March 2008 report in The Journal of Infectious Diseases, for example, found that zinc lozenges cut the duration of colds to four days from seven days, and reduced coughing to two days from five.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "There is no question regarding the availability of products containing zinc; however, as the writer points out, the most effective formulation and dosage for reducing cold symptoms is currently unknown. \nOf note, the story specifically mentions that zinc lozenges from Coldcure.com were used in many of the trials evaluated in the Cochrane systematic review, but failed to note that they are no longer manufactured.\u00a0", "answer": 1}, {"article": "The company's stock plummeted.\n\"If you think about it, the worst thing that you want is an immune system that's out of control,\" Loke says.\nWhen you first meet Moises Velasquez-Manoff, the first thing you notice is his hair \u2014 or the lack of it.\n\"Then I had like, little bit of peach fuzzy hair growing here and there on my body,\" Velasquez-Manoff says.\nSo the hypothesis is that intestinal worms could possibly reverse these problems, by damping down the immune system.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions that one person obtained worms in Mexico. Otherwise, there\u2019s no information about their availability. In fact, selling worms for therapeutic use is illegal in the U.S.\u2013this should have been mentioned.", "answer": 0}, {"article": "But some pain experts defend the value of the diagnostic tests.\nPatients don't care much about the finer points of diagnostic accuracy.\nThe results appear in the August issue of Anesthesiology.\nBecause the diagnosis of pain can be imprecise, doctors often order multiple tests before treatment.\nOf about 150 patients, the group that got radiofrequency treatment immediately had more people who felt better.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear that nerve blocks are part of \"a common diagnostic technique.\" ", "answer": 1}, {"article": "Half of the patients were given a scan called a computed tomography angiogram, or CTA, in addition to standard diagnostic tests.\nThis is the first study to look at the impact of the scans on long-term survival rates.\nThe scans are cheaper, quicker and safer than angiograms.\nThis involves inserting tubes into the body and heart to check the flow of blood and identify any obstructions that could pose a heart attack risk.\nThe number of patients undergoing additional procedures increased within the first year but had levelled out by the end of the five-year period.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release just how available CTA scanners are.", "answer": 0}, {"article": "Adding small amounts of powdered ginger to food may help take the edge off seasonal allergy symptoms, according to an animal study published online in the Journal of Nutritional Biochemistry. Daily intake of dried ginger significantly reduced sneezing and other signs of allergy in rodents with induced allergic rhinitis, or hay fever.\n\nA major component in ginger, 6-gingerol, suppresses the activation of T lymphocytes, or T cells, a type of white blood cell that plays an important role in sensitizing people to specific allergens,...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that the study used powdered ginger, which it notes is used in cooking. People can deduce from this that powdered ginger is widely available.", "answer": 1}, {"article": "This, sadly, is expected; more than 178 million doses of Gardasil have been given worldwide, and given that huge number it\u2019s a statistical certainty that some young people will die not long after getting them.\nIt also shows that the claims made by anti-vaxxers are wrong, and that people fighting the vaccine because of their own sexual biases are making things far worse.\nWorse, these same people tend to promote abstinence-only education, which has been shown conclusively to be the worst possible sex education; kids taught his way tend to have more pregnancies and more STIs than ones who are taught progressive, healthy sex ed.\nFor example, a young girl died tragically not long after getting the vaccine, and it got a lot of press, but it was later found that she died of a completely unrelated cause.\nIt\u2019s very frustrating; mounds of data show these vaccinations are incredibly low-risk, but it only takes a little bit of doubt and fear to make vaccine rates drop.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that more than 178 million doses of the vaccine have been dispensed, meaning that it is readily available.", "answer": 1}, {"article": "T. Kondo, R. Goto, K. Ono, S. Kitano, M. A. Suico, M. Sato, M. Igata, J. Kawashima, H. Motoshima, T. Matsumura, H. Kai, and E. Araki, \"Activation of heat shock response to treat obese subjects with type 2 diabetes: a prospective, frequency-escalating, randomized, open-label, triple-arm trial,\" Scientific Reports, vol.\ncm in the 7 per week group.\nThe first trial showed that activation of the HSR produced a large therapeutic effect.\nTrial subjects received treatments for 60 minutes each time, and were separated into three groups of 2, 4, and 7 treatments per week.\n\"This device is very easy to use since it simply attaches to the abdomen, and it has a low-impact on the patient.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Even though the researchers advanced from theoretical thinking to animal and human trials there is no discussion of when the device might become available to patients.", "answer": 0}, {"article": "Both have made early detection and treatment more precise.\nRegular colonoscopy physically examines the colon by inserting a lighted probe into the intestine and requires a sedative.\nColorectal cancer is the second leading cause of death among the combined group of men and women who have cancer, according to the National Institutes of Health.\nSuch highly specific screening may allow doctors to detect more abnormal growths, called polyps, when they are as small as .10 mm, so they can be removed before they become full-blown cancer tumors.\nThe CDC says colonoscopy may also be recommended for people experiencing stomach pain, aches or cramps that don't go away, unexplained weight loss and blood in the stool.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The ability of a radiologist to take a virtual stroll through a patient\u2019s bowel \u2014 i.e. the \u201cwalk-through colonoscopy\u201d touted in the article \u2014 is perhaps unique to a single site. The story doesn\u2019t establish whether or where such technology might be available outside of SUNY Stony Brook. But regardless of whether they provide the \u201cwalk-through\u201d capability described here, most academic medical centers have the capability of performing a CT colonoscopy that\u2019s the basis of this approach. Insurance coverage is a major consideration limiting its availability to the average patient", "answer": 0}, {"article": "These hypotheses have now been tested in a study in which rectal cancer patients were randomly assigned to three different treatment arms:\n\u2022 Delayed surgery with short-course (5x5 Gy) radiotherapy followed by surgery after 4-8 weeks.\nHowever, radiotherapy can cause adverse reactions and the optimal radiotherapeutic method and the interval between it and the ensuing surgery have been mooted.\nPreoperative radiotherapy was gradually introduced in the early 1990s, with a consequent improvement in prognosis for people with rectal cancer and reduction in the risk of local recurrence.\n\"Thanks to our results, radiotherapy is recommended to many rectal cancer patients.\"\n\"The results can now be immediately put to clinical use to the considerable benefit of the patients.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Since these are existing treatments have already been in common use for many decades, availability is not an issue.", "answer": 1}, {"article": "Her research group led both studies.\nFor example, a poor test grade or bad performance evaluation might lead to feelings of \"I'm not good enough,\" but the lessons encourage more positive thinking about \"how many exams have you passed, to put this failure in a more accurate light,\" Guille said.\n\"It's very stressful because you're sleep-deprived, you're not eating right ... you're working back-to-back shifts and you're trying to catch up on sleep but you can't,\" Dalechek said.\nAn earlier study of 740 interns found that suicidal thoughts increased almost four-fold during the first three months of residency, said Dr. Constance Guille of the Medical University of South Carolina in Charleston.\nThe research involved about 200 medical interns \u2014 residents in their first post-graduate year, which is often one of the most intense periods of doctor training.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that the study, \u201c..\u00a0used a free online program developed at the National Institute for Mental Health Research at the Australian National University in Canberra.\u201d\u00a0 but provides no additional information about general availability outside of the study.\nThe story should have mentioned the name of the online program that was used for the study in the case that any current residents may want to try it for themselves, or perhaps family members or friends\u00a0of current residents may want to suggest the program\u00a0if they come across the story.", "answer": 0}, {"article": "After a systematic review of medical research on the subject, experts reported that adding an aromatase inhibitor -- a drug that reduces the amount of estrogen produced in the body -- has clearly been shown to reduce the number of tumor recurrences in postmenopausal women compared with the standard drug tamoxifen, which works by blocking the action of estrogen on cancer tumors that are estrogen-receptor positive.\n\"Are [aromatase inhibitors] better than tamoxifen?\nThe drugs can also cause side effects that need to be taken into account when prescribing.\n\"Aromatase inhibitors are clearly associated with osteoporosis and with bone and joint [conditions].\nBut the [financial] costs are much more expensive.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "", "answer": 1}, {"article": "Dr. Scott Stuart, a University of Iowa psychiatry and psychology professor, said his pregnant patients with mild to moderate depression had improved when taking DHA while seeing a counselor.\nHe said more research was needed, but for now, \u201cI think the market is running way out in front of the science.\u201d\n\nScientists agree that DHA, naturally transmitted to a fetus through the placenta in the last half of pregnancy, is important, probably to visual and brain development.\nDr. Jatinder Bhatia, a neonatologist heading the nutrition committee of the American Academy of Pediatrics, said that unless further studies showed no benefit as children got older, he would continue recommending DHA, now in many prenatal vitamins, because \u201cI\u2019m not convinced at this time that we should reverse course.\u201d\n\nMuch about DHA is unknown.\nSeveral studies indicate that babies born prematurely receive too little DHA, and some studies have found that premature babies fed DHA after birth show better cognitive performance or visual coordination later on than preemies who aren\u2019t given DHA.\nThat study\u2019s lead author, Dr. Ingrid Helland of Oslo University Hospital, said that perhaps the benefit shown at age 4 existed at 7 but was difficult to identify amid other developmental factors.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The widespread availability and use of fish oil is clear from the story.\u00a0 Although the story would have helped readers more by reporting on issues of purity, quality control, and difficulties for consumers in assessing the quality of a source or brand.\u00a0 This would have made it clear that this not a straightforward choice to just \"take fish oil.\"\u00a0 ", "answer": 1}, {"article": "\u201cThe findings were exciting,\u201d she said.\nIn coherent breathing, the goal is to breathe at a rate of five breaths per minute, which generally translates into inhaling and exhaling to the count of six.\n\u201cThey show that a behavioral intervention can have effects of similar magnitude as an antidepressant.\u201d\n\nControlled breathing may also affect the immune system.\nIf you have never practiced breathing exercises before, you may have to work up to this practice slowly, starting with inhaling and exhaling to the count of three and working your way up to six.\nAfter 12 weeks of daily yoga and coherent breathing, the subjects\u2019 depressive symptoms significantly decreased and their levels of gamma-aminobutyric acid, a brain chemical that has calming and anti-anxiety effects, had increased.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Availability is not an issue with breathing exercises. As one psychologist and book author quoted in the story says, \u201cBreathing is massively practical.\u201d\nHowever, the story misleads readers a bit by implying that the benefits of breathing exercises can be achieved in just a couple of minutes. In fact, proponents espouse at least 20 minutes of controlled breathing on a daily basis, often over several months, to achieve benefits.", "answer": 2}, {"article": "A common heart drug called a beta blocker was associated with a striking increase in survival for women with ovarian cancer in a study that suggests a possible new strategy for treating a variety of tumors.\n\nResearchers analyzing a database of 1,425 women with the tough-to-treat cancer found those who had taken a certain type of beta blocker lived more than four years longer on average than those who hadn\u2019t been prescribed the drug. The women were taking the medicine to treat high blood pressure or another heart problem, not...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beta blockers are called \u201ccommon heart drugs\u201d in the story and are thus generally understood to be widely available. Beta-blockers first came on the market more than 50 years ago and their use has become widespread as researchers found more applications for this class of drugs. Generic versions are available, making them some of the most affordable prescription drugs.", "answer": 1}, {"article": "The new circulating tumor cell (CTC) chip identified such cells in nearly half of 20 people with early-stage prostate cancer and in two-thirds of people with advanced cancer, providing important prognostic information, researchers at Massachusetts General Hospital reported.\nCombined with annual biopsies, or tissue samples, it was about 70 percent accurate in singling out the aggressive tumors in a small study, John Hopkins University researchers were to report Sunday at the American Association for Cancer Research annual meeting, in Washington, D.C.\n\n\"What we have shown is that using the Prostate Health Index and tissue DNA measurement is informative in separating out patients whose cancers are likely to progress vs. those that are not likely to progress,\" said study leader Robert W. Veltri, an associate professor of urology and oncology at Hopkins.\nIn a study of 2,000 men in the Chicago area, \"we found it to be more accurate than the tests now available, and it also seems to identify the more aggressive prostate cancers,\" he said.\nThe regimen found unfavorable indications for 39 of the cancers -- meaning progression of cancer grade or tumor size -- and favorable for the 32 others, Veltri said.\nBut it was a small study, and \"it will take another year or two to get enough cases to nail down the predictive index,\" Veltri said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0The story mentioned that this test is currently \"awaiting\" FDA approval for use in the US but has already been approved for use in Europe.\nThis type of wording is misleading because it may imply that FDA approval is a done deal. \u00a0It would be better reporting to state that the product is being considered by the FDA for approval.", "answer": 1}, {"article": "That, in turn, could lead to thousands of unnecessary lung scans, causing excess radiation exposure and unnecessary biopsies and surgery.\n\u201cEven in these highly controlled settings, about 1 percent of the people had surgery or a part of their lung removed for something they thought was cancer and it wasn\u2019t.\u201d\n\nLow-dose CT scans expose patients to about the same radiation levels as mammograms.\nIn an interview, Dr. Lepor said that he only offers lung scans to those at high risk, and that he turns people away who are at low risk but want the scan anyway because \u201cthey just want to know.\u201d\n\nDr. Lepor said it would be \u201cimprudent\u201d not to incorporate the latest study data into his practice right away.\nWe know from our own anecdotes that we have saved a lot of lives.\u201d\n\nDr. Lepor said that he had just met a woman who had smoked for 50 years and was concerned about her risk.\nIn the release, Dr. Norman E. Lepor said the scans were an \u201cindispensable\u201d part of annual exams for patients who have smoked for 10 years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of CT scanners to do lung cancer screening was clear from the story.\u00a0 More importantly, though, was the question of interpreting those scans \u2013 with questions raised in this excerpt about the problems even experienced radiologists at major cancer centers had:", "answer": 1}, {"article": "The paper suggests that the drug may one day offer a nonsurgical alternative to \"vertical sleeve gastrectomies\" that have become popular in the battle against morbid obesity.\nBut don't expect to be popping fexaramine any time soon.\nMore than a third of the U.S. population is considered obese.\n\"We can get that whole process of what a meal does without actually having the meal,\" he said.\n\"The drug or the pill is taken orally, and it tricks the body into thinking you\u2019ve eaten a meal.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does caution readers not to expect this drug to be available any time soon.", "answer": 1}, {"article": "But after controlling for those risk factors, \"the difference [in brain aging] is still there so we conclude that omega-3 fatty acids likely explain them,\" Tan said.\nFind out more about brain health at the Alzheimer's Association.\nAdults in the bottom 25 percent also tended to have smaller brain volume overall.\nBrain scans also showed signs of less blood supply in the brains of people with the lowest omega-3 levels.\nThis might include reducing blood pressure and inflammation, he added.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of fish isn\u2019t in question.", "answer": 2}, {"article": "They found that blood test results above certain levels reliably predicted how well patients would respond to commonly prescribed antidepressants.\nIt would accelerate our therapeutic interventions and make them more tailored to the needs of the patient.\u201d\n\nBut further clinical research is needed to see if the findings can be applied in a clinical setting, Hallstrom added.\nThese initial findings are interesting, but, as with all areas of mental health, there is still more research to be done.\u201d\n\nMental health problems, including depression, are estimated to cost \u00a3105bn a year in England.\nDr Cosmo Hallstrom, a spokesman for the Royal College of Psychiatrists, said: \u201cFinding biological markers for depression (and other mental illnesses) has been the holy grail of biological psychiatry.\nThe Royal College of Psychiatrists said that, if it worked, the test could prove to be a key moment in the quest for the holy grail of biological psychiatry.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story acknowledges in the third-to-last paragraph that \u201cfurther clinical research is needed to see if the findings can be applied in a clinical setting.\u201d That\u2019s good\u2013but we would have liked to seen this detail much higher. Also, we would have liked to seen some discussion of how many more steps are in the process\u00a0to develop an effective blood test for clinical use.", "answer": 1}, {"article": "When I began training last year for my first marathon, my running partner Dave Freedholm, an experienced amateur distance runner, impressed on me the need to vigilantly avoid dehydration. His drink of choice was Accelerade. Like Gatorade, the original sports drink, it's packed with sugars and sodium to provide energy and replace the electrolytes depleted in sweat. But it also contains protein, which he said would help my muscles repair themselves more quickly after the punishing training runs he took me on.\n\nSure enough, I never felt much pain until after the marathon itself, and even then I recovered within a couple of days...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that these drinks are widely available. ", "answer": 1}, {"article": "In recent years, doctors have started to focus on inflammation \u2014 the same process that makes cuts red and painful \u2014 as an important contributor to a heart attack.\nThe drug is not currently approved for any heart conditions, but Novartis will likely look at doing more studies to confirm its effectiveness in treating heart disease.\nIn the study, 10,000 people who have already had a heart attack were randomly assigned to get injected with a placebo or different doses of a drug called canakinumab.\nAfter four years, the people who received the drug had a 15% lower chance of having a heart attack or stroke compared to people who didn\u2019t get the drug.\nFor them, it may not be cholesterol so much as inflammation that is driving their heart disease.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes clear that no one is suggesting the drug at present for routine use, and that at present the drug is not cleared for use in heart disease patients.", "answer": 1}, {"article": "When she saw them, she said, \u201cI asked my analyst to rerun the data.\u201d\n\nNow, researchers say, the challenge is to find out why the test missed so many cancers, in particular, those on the right side of the colon, and whether the problem can be fixed.\nIt might be that Canadian doctors were not sufficiently skilled.\nAnd they should do a high volume of screening.\nThey should take at least eight minutes to withdraw an endoscope from the colon.\nIt looks for blood in the stool, which can arise from colon cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly colonoscopy is available.", "answer": 1}, {"article": "They wrote up a plan to test what they called \u201csuperselective intra-arterial cerebral infusion\u201d of Avastin in 30 patients with glioblastomas that had recurred after standard treatment.\nDespite a beautiful scan, the first patient who was treated died in October, from pneumonia and the spread of glioblastoma to his brainstem.\nWith the best treatment, the median survival time is about 15 months.\n\u201cThis will substantially alter the way that chemotherapy is given in the future,\u201d said Dr. John Boockvar, the brain surgeon who devised the trial.\n\u201cThis is a very good start,\u201d Dr. Lonser said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes very clear that the approach described is experimental and not clinically available. It is the subject of a Phase I trial of 30 patients.\u00a0 ", "answer": 1}, {"article": "Craig Horswill, clinical associate professor of kinesiology and nutrition at the University of Illinois at Chicago, says the study adds to the growing body of evidence that suggests strategies for increasing non-exercise active thermogenesis \u2014 defined as spontaneous activity unrelated to a fitness routine \u2014 are needed to help overcome the detrimental effects of prolonged sitting.\nThe device, which is commercially available, was a movable footrest, suspended from the underside of the desk, which enabled the feet to swing, twist or teeter.\nThe findings are published in WORK, a journal affiliated with the Canadian Association of Occupational Therapists and endorsed by the International Ergonomics Association.\n\u201cThis is more evidence that NEAT, something everyone can do throughout the day, may be an important strategy for improving health, and even reducing early death,\u201d said Horswill.\n\u201cThese results suggest that non-exercise active thermogenesis, which we call NEAT, can increase movement and calorie burning, and may have the potential to impact health,\u201d said Horswill, the senior author on the study.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The HOVR device used in the study is commercially available, as the news release says. A search online shows that it can be purchased both from the company website and from Amazon.", "answer": 1}, {"article": "\u201cIt\u2019s a bit like with mobile phones.\nLONDON (Reuters) - Scientists have used an \u201cartificial pancreas\u201d system of pumps and monitors to improve blood sugar control in diabetes patients in the first study to show the new device works better than conventional treatment.\nI see the same thing with this system.\u201d\n\nThe Juvenile Diabetes Research Foundation said last month it was teaming up with U.S. drugmaker Johnson & Johnson\u2019s unit Animas, which makes insulin pumps, and DexCom Inc, which makes continuous glucose monitoring devices, to develop and test an artificial pancreas system.\nThe Cambridge study found their device performed better than a conventional pump, which delivers insulin at pre-set rates and which kept blood sugar levels around normal for 40 percent of the time compared with 60 percent for the artificial pancreas.\nHe said the results were \u201can important stepping stone\u201d toward bringing an artificial pancreas to the commercial market, but predicted several years yet of refinement before it could be used day and night by patients in normal life.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story suggests that it will be several more years before the \"new device\" supposedly tested in this study will be available on the commercial market. But as the competing story in the New York Times makes clear,\u00a0the\u00a0researchers in this study did not test a \"device\"\u00a0per se\u00a0but rather an algorithm that could hypothetically be used to link up a glucose monitor and an insulin pump to create\u00a0a new device for automatically managing blood glucose.\u00a0The\u00a0suggestion that there is a device\u00a0already in testing\u00a0exaggerates the level of progress that\u00a0has been made and will give readers a false sense\u00a0as to\u00a0how close\u00a0this product is to\u00a0becoming a reality.\u00a0 ", "answer": 0}, {"article": "Currently, we\u2019re in limbo as to how to advise patients.\u201d\n\nHe acknowledged that the need for such a study for men is \u201cless compelling\u201d because, in contrast to women, who experience an abrupt drop in estrogen at menopause, often with disruptive symptoms, hormone decline in aging men is far more gradual, and symptoms, when they occur, are commonly viewed as normal signs of aging, not hormone deficiency.\nThe study, in which the men are being randomly assigned to receive the hormone or a look-alike placebo, will also evaluate the hormone\u2019s effects on cardiac risk factors.\nCiting the results of many small studies, Dr. Bremner said, \u201cThere is good evidence that testosterone administration can improve muscle mass and strength and increase bone density\u201d in men with subnormal levels.\nThen again, this may be a realistic population to study, given that many candidates for hormone therapy are likely to have such health issues.\nAmong a sample of 3,369 men aged 40 to 79, researchers at eight European medical centers found that \u201climited physical vigor\u201d and three sexual symptoms \u2014 diminished sexual thoughts and morning erections and erectile dysfunction \u2014 were most closely linked to low levels of testosterone.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study notes that testosterone therapy is available in the U.S. as an\u00a0intramuscular injection, a skin patch\u00a0or gel,\u00a0pellets inserted under the skin, and in oral preparations. \u00a0", "answer": 1}, {"article": "Also known as extended-release naltrexone, the medication won Food and Drug Administration approval for alcohol dependence in 2006 and in 2010 to prevent relapse in post-detox opioid users.\n\u201cWhen I\u2019m on Vivitrol, I can\u2019t get high,\u201d he said.\nA year after treatment stopped, there had been no overdoses in the Vivitrol group and seven overdoses, including three deaths, in the other group.\nThe evidence for giving Vivitrol to inmates is thin but promising.\n\u201cIt does suggest six months wasn\u2019t enough,\u201d said Lee, the lead author.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Information about FDA approval of the drug\u2014in 2006 for alcohol dependence and in 2010 for opioid users\u2014is included in the story.", "answer": 1}, {"article": "nutritional guidelines, which I\u2019ve discussed before, says that coffee is not only O.K.\nIt\u2019s important to remember that we usually conduct those trials to see if what we are observing in epidemiologic studies holds up.\nIf any other modifiable risk factor had these kind of positive associations across the board, the media would be all over it.\nToo much of anything can be bad.\nThere have been two meta-analyses published within the last year or so.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Coffee is everywhere, in every culture, and in every corner of the planet \u2014 and the story mentions places you can get it.\nThere is an intersection in Vancouver with a Starbucks on EVERY corner.\nHave you heard about the new Starbucks that opened in the bathroom of an existing Starbucks?", "answer": 1}, {"article": "For more information: http://www.\nThe third in a series of studies from the Andersen lab involving PD and low-dose lithium, the results add to mounting evidence that low-doses of the psychotropic drug could benefit patients suffering from the incurable, degenerative condition.\nWhile the medication remains the single most effective agent in the management of PD symptoms, long-term use causes its own side effects, among them abnormal involuntary movements or AIMS.\nLow-dose lithium reduced involuntary motor movements - the troubling side effect of the medication most commonly used to treat Parkinson's disease (PD) - in a mouse model of the condition that is diagnosed in about 60,000 Americans each year.\nCitation: The combination of lithium and L-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: relevance for Parkinson's disease therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release makes it clear that lithium is currently available and used for psychiatric illness. Given that the drug is available, it\u2019s conceivable that desperate patients will seek treatment with lithium based on these findings \u2014 which is why it\u2019s all the more important to carefully qualify the results in the headline.", "answer": 1}, {"article": "Scientists in Britain say they have developed a blood and urine test that can detect autism in children.\nThis may help us improve the diagnosis of ASD and point the way to new causes of ASD.\u201d\n\nThe research has been published in the journal Molecular Autism.\nResearchers at the University of Warwick said the test, believed to be the first of its kind, could lead to earlier diagnosis of autism spectrum disorders (ASD) in children who could then be given appropriate treatment much earlier in their lives.\nIt is estimated that about one in every 100 people in the UK has ASD, with more boys diagnosed with the condition than girls.\n\u2022 Note added 27 February 2018: The UK autism research charity, Autistica, provided the following comment to the Guardian: \u201cThis is a small, early-stage study which may explain one biological difference in autism.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentions two damaged proteins, in particular, which researchers found in higher concentrations of the blood of children with ASD, than in blood of children in the control group. We\u2019re not told if the tests for these proteins are routine or highly specialized. Exactly what was found in the urine isn\u2019t mentioned. Therefore, the availability of both the blood and urine tests is unclear.", "answer": 0}, {"article": "Several of Cook's co-researchers work for the company.\n\"We just wanted to see if this is feasible, and this study shows that it is,\" said lead researcher Dr. Mark Cook, of the University of Melbourne and St. Vincent's Hospital in Australia.\nThe prospect of being able to predict seizures is \"very exciting,\" he said, in part because it's the uncertainty of the disorder that can dim people's quality of life.\nBut what's still needed is evidence that this device does improve the quality of patients' lives, Mehta said.\nTHURSDAY, May 2, 2013 (HealthDay News) -- An implanted device that monitors brain activity may offer a way to predict seizures in people with uncontrolled epilepsy, a small pilot study suggests.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about how far away from marketing approval such an approach might be.\u00a0 But we\u2019ll call it satisfactory for at least including this from the independent expert quoted:\n\u201cThis study is an important first step,\u201d said Mehta, who was not involved in the research. \u201cThe next step would be to implant these in a larger sample of patients. And you need to see which groups of patients might be good candidates for this.\u201d", "answer": 1}, {"article": "Cut It Out (Surgically)\n\nAt 32, it just didn't make sense that Daniel Sheiner was exhausted literally from the moment he woke up.\n\"It didn't get any better over the course of the day, and I knew that was not normal,\" Sheiner says.\n\"He had very large tonsils, but his tonsil tissue was also enlarged in the palate area and also at the back of his tongue.\"\n\"What the robot allows you to do is get into a small, confined space without using hands,\" Thaler says.\n\"I would say let's lose the weight; let's use CPAP and see a nutritionist; let's avoid the alcohol and let's see how you do.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not totally clear on this point.\u00a0 The story states this one doctor has done the robotic surgery on only six patients. But it\u2019s not clear if she\u2019s the only one who\u2019s done this surgery.\u00a0 And if not, where else and how often?", "answer": 0}, {"article": "This trial represents an expansion of the Abramson Cancer Center's integrative medicine and wellness services that are available to patients and survivors.\n\"We offer several ways to enhance quality of life, minimize or reduce side effects of cancer and cancer treatment, and promote healing and recovery,\" Vapiwala said.\n\"There may also be a psychosocial benefit that derives from participation in a group fitness activity that incorporates meditation and promotes overall healthiness.\nFurthermore, erectile dysfunction is reported in 21 to 85 percent of all prostate cancer patients, while urinary incontinence is reported in 24 percent of men with this disease.\nThe new, first-of-its-kind study, led by Neha Vapiwala, MD, an associate professor in the department of Radiation Oncology at PSOM and Penn's Abramson Cancer Center, found that general quality of life and measurements of side effects often experienced by prostate cancer patients--including fatigue, sexual health, and urinary incontinence--were stable throughout a course of outpatient radiation therapy among the men participating in an intensive yoga program.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the near ubiquity of yoga classes is well-known, it is not clear how available Eischens yoga classes may be. The release also doesn\u2019t tell us what distinguishes Eischens yoga from other forms of yoga.", "answer": 0}, {"article": "But study author Dong Wang, a graduate student with the departments of nutrition and epidemiology at Harvard T.H.\nAccording to study author Wang, trans fats have been almost eliminated from the food supply, so what is needed next is more taxation on sugary drinks and more regulations requiring salt to be reduced in food.\nAs a result, she said, it's crucial to look at a variety of studies and see if trends hold up.\nTo get insight into the answer, they analyzed the results of seven health and nutrition surveys including almost 34,000 adults aged 20 and older between 1999 and 2012.\nThe researchers extrapolated their findings and estimated that the improvement in diets prevented over one million premature deaths and lowered heart disease cases by almost 9 percent, type 2 diabetes cases by nearly 13 percent and cancer cases by just over 1 percent.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Except possibly for food deserts, healthy foods are generally available. The story makes the case that widespread consumption of healthier foods has had broad public health benefits.", "answer": 1}, {"article": "Before undergoing surgery, cancer patients could be given the Zika vaccine to \"let the viruses hunt down the GSCs [glioblastoma stem cells] and eliminate them,\u201d said virologist Dr. Cheng-Feng Qin of the Chinese Academy of Military Medical Sciences in Beijing, who worked on the study.\nShi said: \u201cScientists may turn the 'bad' side of a devastating pathogen\u2014Zika virus\u2014for potential cancer therapy.\u201d\n\nHowever, he cautioned any potential treatment which could emerge from the study is far from being rolled out.\nHowever, as the disease spreads, it becomes difficult to differentiate healthy brain cells from cancerous glioblastoma stem cells, and the condition is therefore almost impossible to completely remove.\n\u201cFor example, we need to make sure that the therapeutic vaccine virus does not infect and kill normal neurons in humans.\u201d\n\nDr. Harry Bulstrode, brain tumor expert funded by the charity Cancer Research U.K. who is researching how Zika could be used to treat aggressive brain tumors, who was not involved in the study, told Newsweek: \"This study is another interesting piece in the jigsaw, but it is never going to demonstrate what we believe to be the really exciting properties of the virus.\nThe study showed that a live-attenuated Zika vaccine (containing a weakened version of the virus that does not cause disease in humans) could selectively infect and kill human glioblastoma stem cells, explained Shi.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear this treatment isn\u2019t available for use in humans.\nThe story could have put the findings into clearer perspective if it noted that availability for human is at best 5 to 7 years in the future\u2013and actually may never come to pass.", "answer": 1}, {"article": "Eligible media should contact Shealy Molpus, smolpus@acc.org, to receive access to the briefing.\nIt's a freebie and provides critical information that could be lifesaving for some women,\" Hecht said, adding he hopes these findings will prompt clinicians, who rarely report breast arterial calcification, to routinely report not just the presence or absence of breast arterial calcifications but also to estimate and note the amount.\nBecause the study involved women who received both mammography and CT scan for clinical indications, these women may have been more likely than the average woman to have coexisting conditions, although Hecht said these were unrelated to heart disease.\nThe overall accuracy of breast arterial calcification for the presence of CAC was 70 percent, and 63 percent of those with CAC also had breast arterial calcification.\nThere were even fewer false positives among younger patients; researchers said that if a younger woman had breast arterial calcification, there was an 83 percent chance she also had CAC.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The digital mammogram is widely used and available and neither the release or the study seem to be calling for additional testing beyond what is already taking place. So while availability is not specifically addressed, it\u2019s pretty evident from the release that such testing is widely available.", "answer": 1}, {"article": "JACC is ranked No.\nIn an accompanying editorial, Deepak L. Bhatt, M.D., M.P.H., executive director of interventional cardiovascular programs at Brigham and Women's Hospital Heart and Vascular Center and professor of medicine at Harvard Medical School in Boston, said the program is groundbreaking, and follow-up studies to further pinpoint the exact mechanisms by which the program achieved positive effects on young children's health will be vital for implementing the program in other areas and informing the design of future global programs.\n\"It may not only be the cardiovascular health information from the program that is helpful but also the cognitive stimulation from and exposure to positive adult role models, which in turn influence personality traits critical for health behavior and habits,\" Bhatt said.\n\"There is a need for a complete change in the timing of when we deliver care,\" said Valentin Fuster, M.D., Ph.D., senior author of the paper.\nThe study and editorial are part of a comprehensive Population Health Promotion issue of the Journal of the American College of Cardiology focusing on issues that broadly impact public health and the prevention of cardiovascular disease and related conditions.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release mentions that the intervention is part of the SI! program \u2014 but it doesn\u2019t establish what that is or whether it\u2019s something that the wider public has access to. One might presume that the program is used only in a research setting at present, but we don\u2019t know that for sure, and the release should have made this clear.", "answer": 0}, {"article": "\"You're going through all this suffering and stuff and you want to know, am I going to survive?\nAs a practical matter, the goal of researchers is to convince federal regulators to cover the procedure under Medicare and Medicaid, which would open the door to routine use.\nBut researchers are exploring a new use for medical imaging that could shorten the stay in purgatory, possibly revealing within a few days whether chemo is working.\n\"Our hope ... is you might be able to give a single dose of a chemotherapy agent and within a day or two figure out whether the tumor is going to respond,\" says Dr. Michael Graham of the University of Iowa.\nsaid Stevens, 48, of La Jolla, Calif. \"Your whole life is in sort of a limbo.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The treatment is experimental and not currently available. Yet it is not until late in the story that we learn the research is very preliminary. The caveats appear eventually but should have framed the story from the outset.\u00a0 \nThe story allows advocates to offer unsupported speculation that the government may agree to pay for the procedure in \"two or three years\" and new PET technologies will transform cancer treatment within 10 years.\u00a0 \nThe use of the anecdote in the lede implies availability.\u00a0 ", "answer": 0}, {"article": "The study's third co-author is Julie-Andr\u00e9e Marinier, from the Centre de recherche interdisciplinaire en r\u00e9adaptation du Montr\u00e9al m\u00e9tropolitain and \u00c9cole d'optom\u00e9trie at the Universit\u00e9 de Montr\u00e9al.\n\u201cWhat was interesting to note was that it didn\u2019t matter what technology was used to do the magnification: an iPad worked just as well as a traditional device like a closed circuit television system (CCTV),\u201d he says.\nIn Canada, that\u2019s roughly 3.6 million people.\nA study recently described in Good Times Magazine provides the first experimental evidence that the Apple iPad is as good as technology traditionally used in reading rehabilitation for individuals with visual impairment.\nA little over half the participants had age-related macular degeneration, a disease characterized by the deterioration of the small central portion of the retina that is normally responsible for fine detailed vision tasks such as reading.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s common knowledge that consumer tablet computers are widely available so we\u2019ll rate this Not Applicable.", "answer": 2}, {"article": "Colby says if you think of the eye as an old-style camera with film, then the retina is the film.\n\"In order to implant this device, we need to remove the natural lens, or the cataract, and then use a portion of the natural lens to position and support the telescope,\" says Williams.\nSo the take-home message: If you're over 60 and you begin to experience visual loss, get yourself to an eye specialist as soon as possible to see if you can be treated with medication to stabilize and even reverse the vision loss you've experienced.\nWhat happens with age-related macular degeneration is that the center of the retina deteriorates, and people gradually lose sight.\nBut if they're scanning the room to see exactly where the clock is, they use the other eye, which also has end-stage macular degeneration.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this is an experimental study and says that the FDA\u00a0plans to monitor the side effects for five years. We\u2019re not quite sure why this story was coming out now given that the FDA approved this device at\u00a0the beginning of the month.\u00a0(Read about it.)\u00a0How widely available is it? Never made crystal clear. ", "answer": 1}, {"article": "Oct. 25, 2010 -- Aspirin , already linked in some studies to a lower risk of developing colon cancer , may also cut the risk of dying of prostate cancer by more than half, a large study suggests.\nMen who took aspirin gained the greatest benefit, Choe says.\nBy 10 years after diagnosis, 10% of men not taking one of these medications had died from prostate cancer vs. 4% of those who took an anticlotting medication.\n\"We have to be sure the benefits outweigh the risks before we recommend this to patients.\"\nAlso, 43% of men who didn\u2019t take anticlotting medications had a recurrence of their cancer, compared with 33% of men who did take them.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe study looked at the use of available anticoagulant medications.", "answer": 1}, {"article": "Atopic dermatitis (AD) is a chronic inflammatory skin condition characterized by red, swollen and cracked skin with intense itching.\nIt has been estimated that approximately 18 million people are living with AD in the U.S. and this disease accounts for up to 20% of patient visits to dermatology offices.\n\"The results of the Phase 2 study suggest that MM36 represents a potentially safe, effective and well-tolerated non-steroidal treatment for mild-to-moderate atopic dermatitis,\" said Linda Stein Gold, MD, director of clinical research, Department of Dermatology at Henry Ford Hospital and co-author of the article.\n\"We believe these Phase 2 results demonstrate compelling evidence of MM36's capacity to be a leading topical PDE4 inhibitor and are aggressively developing MM36 for atopic dermatitis in the US.\nThe successful results of the Phase 2 trial of MM36 have been published by the Journal of the American Academy of Dermatology (JAAD), the leading peer-reviewed journal in dermatology.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although industry-sponsored releases must avoid \u201cforward looking\u201d predictions about future drug approval, the release would have added useful information if it had noted whether this phase 2 trial would be followed by phase 3 trials. As it stands there is no way to gauge if or when this product will be available.\nIt seems overly optimistic to make this statement based on a phase 2 study: \u201cMM36 is expected to be the 2nd topical PDE4 inhibitor available in the US and may offer unique benefits for patients suffering from AD.\u201d ", "answer": 0}, {"article": "Tens of thousands?\nThe way the study was done, he says, \"does not allow one to conclude\" that Provenge is working because it mobilizes the immune system specifically against prostate cancer.\nThe primary mystery is how Provenge extends life, since it doesn't shrink prostate tumors, as far as anyone can tell.\n\"Prolongation of survival without a measurable antitumor effect is surprising,\" writes Dr. Dan Longo of the National Institute on Aging in a NEJM editorial.\nLongo, the NEJM editorialist, says he'd be more convinced if the placebo patients had received infusions of white blood cells that had been exposed just to the general immune-stimulating part of the Provenge treatment, without the prostate antigen part.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story is clear the drug was just approved by the FDA and that \"Dendreon, the Seattle-based company that makes Provenge, says there\u2019s a waiting list for the drug. The company estimates 100,000 American men have the kind of hormone-resistant, metastatic cancer the drug is approved to treat. But the company can only make enough at this point for 2,000 patients in the first year.\"", "answer": 1}, {"article": "\"Amazing,\" said Campbell with a smile.\n\"Being able to repair, in some way, a function that has been lost is a very exciting thing,\" Del Priore said.\n\"This is really the first step toward a really bionic eye,\" said Aries Arditi, a senior fellow in vision science at Lighthouse International, a nonprofit advocacy group for the blind and one of the study sites for the artificial retina.\nThe shape is communicated to the brain -- the idea being that Campbell might one day perceive some semblance of a shape of that tree.\n\"Patients were able to do things that we would not have anticipated with so few electrodes,\" Mech said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story plainly says that only 14 people in the U.S. are involved with a study of the artificial retina device, making it clear it\u2019s not in clinical use. ", "answer": 1}, {"article": "Moffitt is the No.\nIn order to determine if the HER2-dendritic cell vaccine is safe and effective, the researchers performed a clinical trial in 54 women who have HER2-expressing early-stage breast cancer.\nThis suggests that strategies that can restimulate the immune system to recognize and target HER2 early during cancer development may be effective treatment options.\n6 cancer hospital in the nation and has been listed in U.S. News & World Report as one of the \"Best Hospitals\" for cancer care since 1999.\nPatients were injected with a dose of their personal dendritic cell vaccine once a week for 6 weeks into either a lymph node, the breast tumor, or into both sites.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "There\u2019s no information on where to get this treatment, whether it\u2019s widely available, and if not yet available when it might be approved as a treatment for breast cancer.", "answer": 0}, {"article": "April 18, 2011 -- The FDA has approved a new noninvasive portable device for the treatment of a deadly type of brain tumor. The device uses electrical fields to slow and possibly reverse tumor growth.\n\nThe device, manufactured by Novocure, is called the NovoTTF-100A System and is meant for adults with glioblastoma multiforme that recurs or progresses after chemotherapy and radiation treatment.\n\nGlioblastoma multiforme is a common type of brain cancer, and the tumor is highly resistant to standard treatments, such as surgery, radiation, and chemotherapy, the FDA says in a statement.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The purpose of the story was to announce FDA approval of the new device, so it\u2019s clear that it\u2019s not widely available yet.", "answer": 1}, {"article": "Recent tests show the cancerous nodules in Mejia's lungs are shrinking, and she hopes for more good news after scans later this summer.\nWhile prenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders such as Down syndrome, new research shows certain types of tests may also reveal markers of cancer in mothers.\n\"If there is cancer, the tumor is shedding DNA into the mother's blood as well and that is what is accounting for this imbalance,\" study author Dr. Diana Bianchi, who serves on an advisory panel for the company, told CBS News.\nThe study, funded by Illumina, a maker of one non-invasive prenatal test, looked at eight women with abnormal test results.\n\"I am thankful for every minute I get to spend with them,\" she said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Although the availability of these new tests is not specifically addressed, the story does note that \u201cprenatal testing is widely used for pregnant women at risk of having babies with chromosome disorders\u201d \u2014 implying that the new tests are one such option. We\u2019ll award a Satisfactory on that basis. The story could also have noted that the new test are recommended by the American College of Obstetrics and Gynecology for some women. Usually they are offered for women over 35 or with other risk factors for a fetus with Down syndrome or certain other chromosomal abnormalities.", "answer": 1}, {"article": "While 19.5 percent of patients who received only the placebo injections were judged to have met the trial\u2019s specified clinical endpoint \u2014 at least a 20 percent reduction in the number of tender and swollen joints \u2014 the response rate among those getting the real drug every four weeks was 53.3 percent.\nThe drug, an injectable monoclonal antibody, is already commercially available for the treatment of psoriasis, for which it has been remarkably effective, said Genovese.\nHowever, despite the availability of TNF inhibitors, \u201conly about half of psoriatic arthritis patients who are given TNF inhibitors get better,\u201d said Genovese.\nFor the last decade or so, Genovese said, another pro-inflammatory substance called IL-17 has been drawing the attention of immunologists focusing on psoriasis and psoriatic arthritis.\nThose getting the drug every two weeks didn\u2019t do any better and were slightly more prone to side effects, such as a mild reaction at the injection site.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the drug has been FDA approved and is available for patients with psoriasis and that Lily has applied for FDA approval for use in patients with psoriatic arthritis as well.", "answer": 1}, {"article": "Weiner conducted much of the research leading to Amyvid's approval.\nLast week, the FDA approved an agent called Florbetapir F 18 injection (to be marketed as Amyvid), which will allow physicians using a positron emissions tomography (PET) scan to detect the presence and extent of amyloid plaques in patients concerned about declining mental function.\nFor now, says Weiner, there is \"no consensus\" on which patients should get the costly new PET scans that use Amyvid, and large insurers such as Medicare and Medicaid have not made decisions about coverage for such tests.\nThe FDA says that Amyvid \"is not a test to predict the development of AD-associated dementia\" in those who have no problematic symptoms.\nThe \"real game-changer,\" he says, will be when one of the many experimental therapies under study for Alzheimer's disease succeeds in blocking or reversing its progress.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The product\u2019s approval by the FDA does not mean that testing will be widely accessible in the near future. The statement from Eli Lilly explains why: \u201cBecause Amyvid loses over half of its radioactivity every two hours, Amyvid must be distributed directly from a radiopharmacy to the imaging centers where it will be administered within several hours. Beginning in June, a limited number of radiopharmacies will be distributing Amyvid with the goal of making the product available in more areas as soon as possible.\u201d", "answer": 0}, {"article": "For now, he suggested that people choose olive oil and other unsaturated fats over saturated fats (found largely in meat and dairy) and trans fats (found in some processed foods, like crackers, cookies and chips).\nOlive oil is one part of the Mediterranean diet that has been tied to heart benefits.\nThe findings, reported in the journal Neurology, hint that the well-known connection between olive oil and heart disease might extend to stroke as well.\nAnd after they did, olive oil was still linked to a lower stroke risk.\nOlive oil is a key ingredient in the so-called Mediterranean diet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of olive oil is not in question.", "answer": 2}, {"article": "DPPOS proved that intensive lifestyle changes resulting in even modest weight loss reduced development of type 2 diabetes by 34 percent, compared with people at high risk for diabetes who only took a placebo and didn't alter lifestyle.\nThe blood-sugar level for a healthy adult, measured as milligrams of glucose per deciliter, is generally 70 to 100 mg/dl.\nFirst published on October 29, 2009 at 12:00 am\n\nCorrection/Clarification: (Published Oct. 30, 2009) The educational position of Elizabeth M. Venditti was reported incorrectly in this story as originally published Oct. 29, 2009, \"Pitt program to prevent diabetes shows promise.\"\nAs a result, Mr. Held, 78, of Whitehall, lost 20 pounds to his current weight of 146 pounds.\nMore than 24 million people in the United States have diabetes, which is a main cause of kidney failure, heart disease, stroke, limb amputations and new-onset blindness.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The reporter fails to mention how and where diabetes prevention programs are available.\nLifestyle-modification diabetes prevention programs are a staple offering of hospitals, community centers, insurance companies and corporate wellness programs. The article could at least have mentioned this\u2013and provides a local resource\u2013to allow readers to follow up if they wanted to.\nMany people with high blood sugar but not diabetes take metformin as prevention. It would be useful to know how widely used the treatment is. ", "answer": 0}, {"article": "Amid a growing body of evidence on the health impacts of the sport, the consensus aims to help current and would-be players maximise the health pros and minimise the health cons of golf, and to guide policy-makers and industry leaders on how best to make golf more inclusive and accessible and so encourage more people from all walks of life to take up the sport.\nThe sport needs to be more inclusive and welcoming of people from all walks of life and ethnic backgrounds, and any such initiatives should be supported, it says.\nCompared with other sports, the risk of injury is moderate, but as it's an outdoor activity, golfers may be more at risk of skin cancer.\nIt can provide moderate intensity aerobic physical activity, and its health benefits are greatest for players (and spectators) who walk round the course rather than opt for a golf cart.\nAgreement was reached on 79 statements in three areas.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Golf is widely available worldwide. But as suggested in the release it may be prove unaffordable for many.", "answer": 1}, {"article": "While the most pressing need, from the perspective of the global burden of disease, is low-and middle-income countries, it's equally relevant in a country like Australia where we're still achieving only 40%-50% control rates for high blood pressure.\"\nThe researchers tested an entirely new way of treating hypertension by giving patients three drugs, each at half dose, in a single pill for early treatment of high blood pressure.\nWith high blood pressure the leading cause of disease burden worldwide, it's expected the findings published in JAMA will change guidelines globally.\nThis is not only time inefficient, it's costly.\nWe also know that many doctors and patients find it too complicated and often don't stick to the process.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s implied (but not made very clear for readers) that the pill is in trials and, therefore, not commercially available.", "answer": 1}, {"article": "But that's only good if the treatment works.\nFor patients who must go on to receive surgery, by selecting them up front, we can spare them the complications that may occur when the voice box is removed following multiple cycles of chemotherapy with radiation,\" adds study author Francis Worden, M.D., professor of hematology/oncology.\n\"In trying to match the biology of the tumor to the treatment, all of the patients get better outcomes,\" says study author Gregory T. Wolf, M.D., professor and chair emeritus of otolaryngology - head and neck surgery at Michigan Medicine.\nFor the most advanced patients, 50 percent survival was the norm, whether patients had surgery to totally remove the voice box or alternative treatment with chemotherapy and radiation to try to avoid surgery.\nAfter a decade of using this approach, researchers are reporting \"exceptional\" survival rates nearing 80 percent, even for the most advanced patients.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this approach to determining the best course of treatment could be implemented at any point \u2014 there are no new technologies or drugs involved. But the release does a particularly good job of addressing this, since it highlights a relevant challenge: \u201cThe induction approach can be done anywhere, but requires intense collaboration among surgeons, medical oncologists and radiation oncologists. All three must be involved to assess the patient and refer to the appropriate therapy.\u201d Communication between all of the practitioners involved in the case of any given patient can be a significant challenge, and is well worth mentioning.", "answer": 1}, {"article": "They did so to offer support, but also to spread awareness, because they say too often life and death for someone having a cardiac arrest comes down to chance. If a bystander performs CPR while medics are on their way, survival rates more than double, doctors say.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article did not gather or report any information about the number of individuals already trained in Philadelphia or in other major cities (such as Seattle) where records have long been kept related to\u00a0bystander CPR training and use. And while it says the need to train more people is \u201cacute,\u201d it doesn\u2019t tell us whether the problem is a lack of available training sessions or the failure to take advantage of those opportunities. The lack of data contributes to the reader\u2019s misunderstanding of the urgency for CPR training.", "answer": 0}, {"article": "But Cao doesn't think people should start taking aspirin to prevent cancer until more research is done.\nSome, though not all, previous studies have indicated that aspirin might slightly lower risk of certain other cancers, including breast cancer, prostate cancer and lung cancer, he added.\nWhile not common, aspirin can cause serious, even occasionally fatal, stomach bleeding, even at low doses, he said.\nSo the more aspirin taken, the more the risk was reduced.\nMoreover, the benefit of aspirin in reducing overall cancer risk appeared to depend on how much one took.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "No explicit mention is made of aspirin\u2019s availability, but the drug is widely known to be commonly available, and the story certainly conveys that impression.", "answer": 1}, {"article": "The study, \"Efficacy and Safety of an Injectable Combination Hormonal Contraceptive for Men,\" will be published online at http://press.\n\"The study found it is possible to have a hormonal contraceptive for men that reduces the risk of unplanned pregnancies in the partners of men who use it,\" said one of the study's authors, Mario Philip Reyes Festin, MD, of the World Health Organization in Geneva, Switzerland.\n\"More research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception,\" Festin said.\nOther authors of the study include: Hermann M. Behre of Martin Luther University of Halle-Wittenberg in Halle, Germany; Michael Zitzmann of the University of M\u00fcnster in M\u00fcnster, Germany; Richard A. Anderson of The University of Edinburgh in Edinburgh, United Kingdom; David J. Handelsman of the University of Sydney and Concord Hospital in Sydney, Australia; Silvia W. Lestari of the University of Indonesia in Jakarta, Indonesia; Robert I. McLachlan of Monash Medical Centre in Melbourne, Australia; M. Cristina Meriggiola of the University of Bologna in Bologna, Italy; Man Mohan Misro of the National Institute of Health & Family Welfare in New Dehli, India; Gabriela Noe of the Instituto Chileno de Medicina Reproductiva in Santiago, Chile; Frederick C. W. Wu of Manchester Royal Infirmary in Manchester, U.K.; Ndema A. Habib and Kirsten M. Vogelsong of the World Health Organization of Geneva, Switzerland; and Marianne M. Callahan, Kim A. Linton and Doug S. Colvard of CONRAD, East Virginia Medical School, a reproductive health organization based in Arlington, VA.\nThe research was co-sponsored and funded by UNDP/UNFPA/UNICEF/WHO/World Bank Special Program of Research, Development, and Research Training in Human Reproduction in Geneva, Switzerland, and CONRAD (using funding from the Bill & Melinda Gates Foundation and the U.S. Agency for International Development).\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The study does not give the impression that injectable hormones for men are readily available. In fact, it quotes a researcher stating that \u201cmore research is needed to advance this concept to the point that it can be made widely available to men as a method of contraception.\u201d\u00a0 However, it could have mentioned that in addition to safety issues, there are other barriers to making male injections widely available. For example, a drug company would have to be willing to make it and sell it at an affordable price.", "answer": 1}, {"article": "Related: Obesity Crisis: Two Billion People Now Overweight and U.S. is One of the Fattest Nations on Earth\n\nAnother benefit from intermittent dieting?\nAnd while it\u2019s common to regain a few pounds after returning to previous eating habits, the two-week dieters kept the pounds off, maintaining a nearly 18-pound loss six months after the study.\n\"I was really impressed that they still saw almost a two kilogram weight loss during that last period at the end of the four months,\" she tells Newsweek.\nFor those who just can\u2019t give up grains (or regular eating), a new study indicates that being less restrictive is actually better for your waistline.\nPaleo has a devout following who swear by its protein-heavy meals, while intermittent fasters believe that forgoing food for hours on end (which varies, but can include skipping meals for an entire day), provides the best results.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It was pretty clear from the article that this was a small study and the absence of any specific information about the diet itself would lead a reasonable reader to conclude that this one is not commercially or otherwise available. That doesn\u2019t mean people won\u2019t try to devise one on their own.", "answer": 2}, {"article": "Why use the traditional approach if the laparoscopic technique is better in some ways?\n\"It's as if you had a leak in a tire that's ballooned out,\" Brunt said.\nThe study \"confirms what a lot of surgeons who do both procedures know already,\" Brunt said.\nThe traditional approach may be appropriate when it's too risky to place patients under general anesthesia, Brunt said, such as in elderly patients and those with multiple health problems.\nThe procedures are designed to reduce the bulge of the hernia and make a patch so it doesn't protrude again.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both approaches seem to be widely available, so the fact that the story didn\u2019t discuss this shouldn\u2019t be held against it. We\u2019ll rule it not applicable.", "answer": 2}, {"article": "She's a breast surgery fellow at Massachusetts General Hospital and Brigham and Women's Hospital in Boston.\n\"We believe formal risk assessment is essential for women ages 40 to 44 in order to identify those who require screening mammography to start at the age of 40, and those who would qualify for screening MRIs and genetic testing,\" Plichta said.\nThe researchers also found that 32 percent of the women met the groups' eligibility standards for regular screening MRIs, and 25 percent would be eligible for genetic testing, Plichta said.\nThe finding is important because the latest guidelines on mammograms advise that most women can wait until the age of 45 or 50 to start having annual screenings.\nThe study also found a significant percentage of women would qualify for other breast screening methods, including breast MRI and genetic testing, Plichta said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned that breast cancer risk assessments are not normally performed in women ages 40-44 years, but didn\u2019t elaborate if breast cancer risk assessments are routinely completed in doctor\u2019s offices or if a woman would need to see a specialist to have one.", "answer": 0}, {"article": "The AHA further breaks down the unsaturated-fat advice by suggesting that people devote about 5% to 10% of their daily calories to foods containing linoleic acid.\nThen, over the ensuing decades, it became clear as science progressed that there were multiple types of polyunsaturated fats, and these compounds potentially have distinct biochemical and health effects.\u201d\n\nThere has been some evidence to suggest that omega-6 fatty acids, for example, may trigger inflammation, a condition that is linked to an increased risk of heart problems, while omega-3 fatty acids, found in deepwater fish like salmon, tend to inhibit inflammatory reactions.\nThe difference came down to the specific type of fats that make up these foods \u2014 animal and dairy fats tend to be saturated, which means all of the free bonds available in a chain of carbon atoms are bound to hydrogen atoms, while plant fats are unsaturated, meaning some of carbon atoms have double bonds with each other.\nBut in the latest study on fats published in the BMJ, researchers found convincing evidence that not all plant fats are created equal and that linoleic acid, or omega-6 fatty acids, may be associated with a higher risk of early death from any cause, as well as increased risk of heart disease and death from heart-related conditions.\nFor decades, the message about fats has been relatively simple \u2014 reduce the amount of oils and fats you eat from animal and dairy products (less red meat and cheese) and substitute them with healthier fats from plants or fish (olive oil, omega-3 fatty acids).\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "As with the competing HealthDay story, there really wasn\u2019t enough information about the fatty acid composition of different vegetable oils, including\u00a0which ones are rich sources of linoleic acid (e.g. safflower oil and corn oil) and which ones\u00a0have a balance of omega-3 and omega-6 fats (e.g. canola, soy). There\u2019s still good evidence that the latter group are healthier than saturated fats. As with the previous criterion comment, it would have not taken much space to explain this to readers.", "answer": 0}, {"article": "MONDAY, Oct. 25, 2010 (HealthDay News) -- One of the world's most ubiquitous and pedestrian drugs -- aspirin -- may cut the risk of dying for men who have prostate cancer that has not yet spread beyond the gland, a new study suggests.\nThe study included 5,275 men diagnosed with prostate cancer that had not yet spread beyond the prostate gland and had been treated with surgery or radiation.\nThis protects them from immune cells and also helps them stick to their next location, Choe explained.\nThis trial, the largest of its kind, involved about 1,200 men who were randomly chosen to receive hormone therapy alone or a combination of that and radiation.\nThe U.S. National Cancer Institute has more on prostate cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe study looked at the use of available anticoagulant medications.", "answer": 1}, {"article": "It only takes an hour in a chemical bath to attach little bits of myelin to the nanoparticles of PLG.\nThis worked just as well in mice.\nHowever, it was hideously expensive.\nIt doesn\u2019t break down and contains a compound, styrene, that may cause cancer.\nCurrently, the main treatment is to suppress the immune system, an approach that can leave patients vulnerable to infections and cancer.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the treatment is not currently available.", "answer": 1}, {"article": "But tests of the concept since the late 1980s have been overwhelmingly disappointing.\nWhile the good results in two patients are encouraging, \"in terms of response rates, the overwhelming data is that T cells, even in high numbers, are inadequate to mediate sufficient anti-tumor effects,\" Lotze said.\nThe new report, however, is believed to be the first time that genetically engineered immune system cells -- specifically, T lymphocytes -- have produced the same effect.\nThe report, published online by the journal Science, is the latest result of a three-decade effort by surgeon Steven A. Rosenberg to find ways to manipulate the human immune system to fight cancer.\nIn the study, Rosenberg and his colleagues took lymphocytes from the blood and inserted into them genes for a receptor capable of \"recognizing\" a protein on melanoma cells called MART-1.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article states that for now only 17 patients have undergone the experimental approach as part of an ongoing and novel study and mentions that the researchers have recently applied to the FDA for approval to conduct a clinical trial in several hundred patients. If approval is obtained, then it is possible that patients without other treatment options might be able to participate in the trial. The article did not specifically state that the approach is not widely available yet, but this can be inferred. However it is important for patients to understand that participation in a trial is not the same as receiving treatment. ", "answer": 1}, {"article": "Vinson, whose research focuses on plant polyphenols and their effects on human health, said it appears that green coffee bean extract may work by reducing the absorption of fat and glucose in the gut; it may also reduce insulin levels, which would improve metabolic function.\nSubjects did not change their calorie intake over the course of the trial.\nIn fact, it is already available as a naturopathic medicine and antioxidant.\nIt would be difficult to take without a lot of water, Vinson reported.\nAltogether, they reduced their body fat by 16%, on average.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One can infer the availability of the extract from the story.", "answer": 1}, {"article": "As part of the new study, published online Monday in the journal Lancet, researchers examined the cancer death rates of 25,570 patients who had participated in eight different randomized controlled trials of aspirin that ended up to 20 years earlier.\nThe specific dose of aspirin taken did not seem to matter \u2014 most trials gave out low doses of 75 to 100 milligrams \u2014 but the participants in the longest lasting trials had the most drastic reductions in cancer death years later.\n\u201cThere\u2019s been a lot of work over the years showing that certain compounds can increase the risk of cancer, but it\u2019s not been shown before that we can reduce the risk with something as simple as aspirin.\u201d\nMany Americans take aspirin to lower their risk of heart disease, but a new study suggests a remarkable added benefit, reporting that patients who took aspirin regularly for a period of several years were 21 percent less likely decades later to die of solid tumor cancers, including cancers of the stomach, esophagus and lung.\nParticipants who had been assigned to the aspirin arms of the studies were 20 percent less likely after 20 years to have died of solid tumor cancers than those who had been in the comparison group taking dummy pills during the clinical trials, and their risk of gastrointestinal cancer death was 35 percent lower.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that \u201cMany Americans take aspirin to lower their risk of heart disease\u201d but not necessarily for a cancer benefit.", "answer": 1}, {"article": "Total hip replacement surgery is increasingly common, with more than 300,000 procedures done every year in the U.S.\n\"The people who are against the whole idea for same-day discharge for hip replacement are concerned about the very rare instances where somebody could develop a blood clot that goes to the lung, or a fracture of some sort,\" said Davidovitch.\nThere are two common surgical approaches for a total hip replacement: anterior, which involves entering surgically through the front of the hip, and posterior, or entering surgically through the side or buttocks.\nAnd to be quite honest, if the pain is controlled and the patient is healthy and medically completely stable there is no reason for them to be in the hospital.\nBut it's not the surgical approach alone that allows some of his patients to go home the same day -- it's a combination of what happens before, during and after surgery.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story offers examples of hospitals currently offering \u201csame-day\u201d hip replacements. If anything the story understates the availability of the procedure.\nHowever, the story could have been more clear about who this procedure is most available to, since this won\u2019t be the right option for some people. For example, if they don\u2019t have help at home, or if they live far from the hospital.", "answer": 1}, {"article": "\"Stem cell therapies show great promise as a treatment for heart injuries, but 24 hours after infusion, we found that less than 10 percent of the stem cells remain in the injured area,\" Dr. Eduardo Marban, director of the Cedars-Sinai Heart Institute in Los Angeles, said in a news release from the institute.\nThe strategy appears to make it more likely that the heart will retain the cells, potentially boosting the power of cardiac stem cell therapy.\n\"This remarkably simple method could easily be coupled with current stem cell treatments to enhance their effectiveness.\"\nWe needed to find a way to guide more of the cells directly to the area of the heart that we want to heal.\"\nThen they injected the cells into rats that had heart attacks and tried to manipulate the cells with a toy magnet.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story barely implied that there is still work to be done before this is available for people.\u00a0 Barely satisfactory. ", "answer": 1}, {"article": "From a crusty baguette to a big thick steak, some foods may be hard to digest, particularly as we age. Enzyme capsules taken before a meal can relieve discomfort by helping the body to break down problem foods, say companies that sell the pills. Doctors say some enzyme supplements work well, but others need more human studies.\n\nDigestive enzymes are proteins that work like scissors to break down foods. The pancreas, where many of these enzymes are made, can slow down as we age, which can result in bloating and other gastrointestinal...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The study provides the names of products that are available over the counter. Readers should be able to use this information to track down the products if they want to buy them.", "answer": 1}, {"article": "But previous studies suggest more than 50 percent of these biopsies are unnecessary and can result in pain, worry, infertility and higher health care costs.\nThe new urine test, they say, is different because it analyzes not only multiple sources of human cellular DNA altered by precancerous changes, but also DNA from HPV that is sexually transmitted and causes virtually all cases of the disease.\nTwo commercial tests based on markers of DNA chemical changes called methylation, released in Europe last summer, require Pap smears or swabs of cervical tissue, and show 64 percent sensitivity in identifying similar lesions, according to senior investigator Rafael Guerrero-Preston, Dr.P.H., M.P.H., assistant professor of otolaryngology-head and neck surgery at the Johns Hopkins University School of Medicine and member of the Johns Hopkins Kimmel Cancer Center.\n\"Our urine test would serve as a molecular triage,\" he says, \"at times supplementing Pap test information.\nUsing all four genes, the test now had a sensitivity of 90.9 percent and a specificity of 60.9 percent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "All depends on a reader\u2019s understanding of the nature of a proof-of-concept study.\u00a0 This urine test is not yet available, but that will be murky to non-specialists unless the term is defined. Reading between the lines it is evident that further testing is needed before it can be used as part of routine care. ", "answer": 0}, {"article": "In March of this year, based upon earlier studies utilizing the test, Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, issued a draft local coverage determination (LCD) for the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nIt is estimated that 50,000 patients a year may be eligible for and benefit from the Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 test.\nThis question weighs heavily on doctors and patients, but now, with the Oncotype DX AR-V7 test, we can provide them the confidence to know whether continuing with hormonal therapy or switching to chemotherapy will result in better survival outcomes,\" said Ryan Dittamore, chief of medical innovation at Epic Sciences and a co-author on the study.\nThe blood test called, Oncotype DX\u00ae AR-V7 Nucleus Detect\u2122 is commercially available in the U.S. through Epic Science's partnership with Genomic Health, Inc. (NASDAQ: GHDX).\nThe PROPHECY study investigated the AR-V7 test in patients receiving ARSi therapy and demonstrated that patients who tested positive had worse survival by all measures and had no clinical benefit from ARSi therapy.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release said the test, Oncotype DX AR-V7 Nucleus Detect, is commercially available in the U.S. However, it didn\u2019t clarify whether it\u2019s FDA-approved for testing patients with prostate cancer. Because the test is not currently covered by Medicare, for those patients the test may only be available as an out-of-pocket expense.", "answer": 1}, {"article": "This is really about patient care.\n\u201cThe femoral artery is the traditional route, but when we go in through a vessel in the wrist, we see less bleeding, fewer complications, less pain and discomfort, higher patient satisfaction, shorter hospital stays, and lower costs.\u201d\n\nPatients may undergo coronary angioplasty \u2014 also called percutaneous coronary intervention (PCI) \u2014 to alleviate chest pain or shortness of breath.\nThe researchers estimated that shifting standard practice by 30 percent to the wrist approach, along with same-day discharge, could save the United States $300 million per year.\nDespite the fact that all of these patients were capable of leaving the hospital the same day as their procedures, only about 5 percent of these patients actually were discharged without having stayed overnight.\nThe research, published Feb. 20 in JACC: Cardiovascular Interventions, suggests that the lower costs of the wrist approach largely are due to the fact that patients experience fewer complications and can be discharged earlier, compared with procedures that access the heart through the larger, deeper artery in the groin.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It clearly conveys\u00a0that the lower cost variants of angioplasty\u2014use of the wrist artery and same-day discharge of the patient\u2014are available but little utilized among Medicare patients. The use of the wrist entrance method appears very low (9%) among Medicare patients.", "answer": 1}, {"article": "UT Southwestern, one of the premier academic medical centers in the nation, integrates pioneering biomedical research with exceptional clinical care and education.\nWe want to make HIF-2 inhibitors available to patients and are currently carrying out clinical trials,\" said Dr. James Brugarolas, Director of the Kidney Cancer Program, who is leading an $11 million SPORE grant from the National Cancer Institute seeking to translate new discoveries into novel therapies for kidney cancer patients.\nIn a previous report, Dr. Kevin Courtney, Assistant Professor of Internal Medicine and a coauthor of the current study, reported at the American Association of Clinical Oncology annual meeting that HIF-2 inhibitors were safe in patients and had activity even in heavily pretreated patients.\nOver the course of a decade, the laboratories of Dr. Richard Bruick, Professor of Biochemistry, holder of the Michael L. Rosenberg Scholar in Biomedical Research, and a coauthor of the current study, and Dr. Kevin Gardner, Adjunct Professor of Biochemistry, solved the structure of HIF-2\u03b1.\nTraditionally, proteins like HIF-2 were disregarded as drug targets because their shape made it nearly impossible to design drugs against them,\" Dr. Brugarolas said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear this is an experimental drug, so experimental it doesn\u2019t even have a name, just a codename: PT2399.", "answer": 1}, {"article": "PROVIDENCE, R.I. [Brown University] -- To the tantalizing delight of chocolate lovers everywhere, a number of recent studies employing various methods have suggested that compounds in cocoa called flavanols could benefit cardiovascular health.\nThe greatest effects were seen among trial volunteers who ate between 200 and 600 milligrams of flavanols a day (based on their cocoa consumption).\nIn addition to Lin and Liu, the study's other authors are Isabel Zhang, Alina Li from Brown University, JoAnn Manson, Howard Sesso and Lu Wang from Brigham and Women's Hospital.\n\"We found that cocoa flavanol intake may reduce dyslipidemia (elevated triglycerides), insulin resistance and systemic inflammation, which are all major subclinical risk factors for cardiometabolic diseases.\"\nAll studies were small and of short duration, not all of the biomarkers tracked in these studies changed for the better, and none of the studies were designed to test directly whether cocoa flavanol consumption leads to reduced cases of heart attacks or type 2 diabetes.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that cocoa flavanols can be obtained from various sources including drinks (cocoa) and dark chocolate. It\u2019s common knowledge that these are widely available. It\u2019s less widely known that dietary cocoa flavanol products are available and it would have been useful to point that out.", "answer": 1}, {"article": "Non-smokers without symptoms generally are not screened for lung cancer in the U.S.\n\u201cThose are some of the things I worry about.\u201d\n\nHer study showed that 300 middle-aged smokers would need to be screened with CT scans to prevent one death from lung cancer.\nIn another study published by Kondo and colleagues \u2014 this one looking at lung cancer screening in smokers \u2014 five-year survival rates were also highest in those screened with CT scans.\nThere and in Canada, the lung cancer debate has centered around how often to screen smokers, and until what age screening should be done, Roberts said.\nAnd for some patients, \u201cif you really weren\u2019t going to benefit from the screening...that complication is something you may not have faced,\u201d Berg said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story differentiates between this study\u2019s screening in people who\u2019ve never smoked and the practice in non-Asian countries where most lung cancers are found in people who\u2019ve smoked. It stated:\n\u201cEast Asian countries are more likely to regularly screen non-smokers for lung cancer because biological differences seem to put Asians at a higher risk than other non-smokers, researchers explained.\nNon-smokers without symptoms generally are not screened for lung cancer in the U.S.\u201d", "answer": 1}, {"article": "Naomi Wolf, author of \"Misconceptions: Truth, Lies, and the Unexpected on the Journey to Motherhood,\" blames insurance companies and hospitals, who she says deny women information about their choices.\nCaesareans impede this process.\nThe courts reward action,\" Block says.\nIf something does go wrong, in the eyes of the courts \"a normal birth is a risk.\nNew research into the risks associated with elective Caesareans supports their view.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Clearly Caesarean\u00a0birth is available.", "answer": 1}, {"article": "This gives them a tool.\u201d\n\nNow the looming questions are how to implement risk calculators in doctors\u2019 practices \u2014 and, Owens said, whether that benefits patients\u2019 health in the real world.\n\u201cThis shows that there might be better ways for physicians to choose who gets treated and who does not,\u201d said Dr. Douglas K. Owens of the VA Palo Alto Health Care System in California, who wrote an editorial published with the study.\n\u201cThat\u2019s the hope.\u201d\n\nHe said he thinks electronic health records will be key to putting individualized guidelines into practice.\nA doctor might tell you, for example, what your risk is of developing diabetes in the next 20 years, and how much you could cut that risk if you lose a certain amount of weight (and keep it off).\nIt also factored in what\u2019s known about different types of patients\u2019 responses to various blood pressure medications.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story could have been more explicit about the availability \u2013 or lack thereof \u2013 of the computerized risk calculator in question.\nHowever, a reader should be able to deduce from the following hints that the idea is not in widespread use:", "answer": 1}, {"article": "Men whose prostate cancer comes back after surgery are more likely to survive if, along with the usual radiation, they also take drugs to block male hormones.\n\nThe finding, published Wednesday in The New England Journal of Medicine, comes from a long-running study that experts say will help clarify treatment for many patients.\n\nAfter surgery to remove the prostate, more than 30 percent of men have a recurrence, and until now there has not been clear evidence about the best way to stop the disease from killing them. Most are given radiation, but prescribing drugs to counter the effects of male hormones has been inconsistent.\n\nThe study, paid for by the National Cancer Institute, showed that among men who received radiation and hormonal treatment, 76.3 percent were still alive after 12 years, compared to 71.3 percent who had radiation alone.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies hormone blockers have been around as a technique for decades, but have not been widely used due to their side effects and uncertainty\u00a0surrounding their actual efficacy.\nThe story goes the extra distance in mentioning that the dose of medicine used in this study in long longer employed. It also states that other, similar, medicines are used more commonly now. Finally, it goes on to say that studies are underway evaluating these other drugs.", "answer": 1}, {"article": "That\u2019s Stage IV cancer and it\u2019s almost always deadly at that stage.\n\u201cThis is huge in the melanoma community,\u201d said Tim Turnham, executive director of the Melanoma Research Foundation.\nThere are side-effects, including fatigue, itchiness and rash.\nThe interaction between the two genes lets some tumors escape detection and destruction by immune system cells.\nIt was bad enough for 8 percent of patients that they stopped taking it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0makes it clear that Keytruda was approved by the FDA in 2014 and is commercially available.", "answer": 1}, {"article": "My entire head throbbed and stung.\u201d\n\nKaufman, who lives in Los Angeles, visited dozens of doctors, trying every option, including pain clinics, holistic remedies, Botox shots, and even hypnotherapy.\n\u201cIt's not a pill, it's an injection that stays in the system for a long period of time and is continuously blocking that CGRP mechanism of migraine.\u201d\n\nResults from several pharmaceutical trials are expected either later this year or in early 2018.\nShe feels like a different person who no longer has to shy away from social commitments.\nAnother advantage: it could lead to a decrease in the amount of medications used by patients to handle headaches acutely.\nHowever, the price tag could be as much as $10,000 a year.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story establishes availability:\nResults from several pharmaceutical trials are expected either later this year or in early 2018. If approved by the FDA, the drug could be available in 2018.", "answer": 1}, {"article": "I would be in my 60s when I had to do this again, and who wants to have surgery unnecessarily when you are 60 something?\"\n\"The silicone implants of today are what we call a cohesive gel \u2014 it's essentially like a jelly.\nSo if the silicone gel leaks, it doesn't travel through the body, it doesn't cause systemic problems.\nBut no one ever told her to get an MRI \u2014 something the FDA now recommends that women with silicone implants get every few years.\n\"They may leak, they may rupture, you may decide you want a different size.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Beginning with a clear description of silicone breast implants\u2026banned in 1992, back five years ago with a concurrent FDA evaluation process\u2026the article does an excellent job of establishing availability.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070805/13knee.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that the Gender Knee is generally available to women who are candidates for total knee replacement.", "answer": 1}, {"article": "Therefore, Ulrik Dalgas is not recommending that all multiple sclerosis patients throw themselves into intensive physical training regimes without first seeking professional advice.\nBut the fact that physical training also seems to have a protective effect on the brain in people with multiple sclerosis is new and important knowledge,\" says Ulrik Dalgas.\nNew research shows that resistance training protects the brain in persons with multiple sclerosis, which may delay the development of the disease\n\nIn the past, multiple sclerosis patients were advised not to exercise for fear of exacerbating the illness.\nIt is not yet clear whether all people with multiple sclerosis can benefit from this type of exercise, as it has not been sufficiently tested in the more severely affected patients.\n\"For the past 15 years, we have known that physical exercise does not harm people with multiple sclerosis, but instead often has a positive impact on, for example, their ability to walk, their levels of fatigue, their muscle strength and their aerobic capacity, which has otherwise often deteriorated.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release provides too little information on what types of exercises are included in the training program and whether they require coaching and monitoring from a trained physical therapist. Is this training widely available for MS patients? We can\u2019t know from this release.", "answer": 0}, {"article": "Jason Dragoo\u2019s Stanford University research team gets 100 to 200 inquiries every day from people interested in joining its clinical trial studying the use of stem cells to treat knee injuries.\n\nThe interest highlights a growing demand for the use of stem cells derived from a person\u2019s own bone marrow or fat to treat orthopedic injuries. Osteoarthritis, a degenerative joint disease where the protective tissue or cartilage around a joint wears down, is a particular focus of inquiry.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story\u00a0implied that there are plenty of places to get these procedures, but lack of evidence and insurance coverage, as well as concerns by the FDA, are standing in the way of availability.", "answer": 1}, {"article": "The study, conducted in conjunction with the University of Washington, involved 56 men who were assigned to receive one of three types of gels: one gel containing both testosterone plus a gel containing one of two doses of the synthetic progestin; or a gel containing testosterone on its own plus a \"placebo\" gel with no progestin.\nThe combination contraceptive needs to undergo further testing before it is commercially available.\nAnother question is how reversible this would be in terms of restoring sperm counts, Alukal said.\nThere's more on contraception at the American College of Obstetricians and Gynecologists.\nOne important and unanswered question is what the long-term side effects of this regimen might be.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states: \u201cThe combination contraceptive needs to undergo further testing before it is commercially available.\u201d", "answer": 1}, {"article": "The study found none.\nThe number of hot flashes among the women taking Lexapro, which is also known as escitalopram, dropped to about five on average after eight weeks--a 47 percent decrease or about 4.6 fewer hot flashes per day, the researchers reported.\nIn the new study, Ellen Freeman of the University of Pennsylvania School of Medicine in Philadelphia and colleagues gave 205 women who were either starting to go through menopause who had already gone through menopause either Lexapro or a placebo for eight weeks.\nAlthough the benefit was modest, it appeared to be significant enough that women might consider trying it, the researchers said.\nBut hormone use plummeted after the federal government's massive Women's Health Initiative shocked women and doctors by concluding the risks of the medication outweighed its benefits.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story did not comment on the availability of Lexapro to treat hot flashes. Although many readers may be aware that\u00a0this drug is approved to treat depression and may therefore be\u00a0used to treat other conditions off-label, the story\u00a0should have spelled this out as the competing WebMD coverage did. \u00a0", "answer": 0}, {"article": "But that may be changing.\nIt\u2019s functioning in your day-to-day life.\u201d\n\nEkstadt has the privilege of being the first person in the nation to get the Raindrop outside of a clinical trial.\nThe procedure to implant the device into Ekstadt\u2019s cornea takes less than 5 minutes: The doctor uses a laser to create a tiny pocket in her cornea and two minutes later the Raindrop is inserted and the procedure is finished.\nThey may work quite well for a period of time but a person's lenses will continue to change with age and, ultimately, the patient may need cataract surgery.\nThe other eye will be for seeing distance, explains Dr. D. Rex Hamilton, director of the Laser Refractive Center at the Stein Eye Institute at the University of California, Los Angeles, and a clinical professor of ophthalmology at the David Geffen School of Medicine at UCLA.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Both of these implants are approved by the FDA, the story tells us, but are they widely available? We are assuming that surgeons need training in how to handle these new devices. Is surgery only available in large metropolitan areas? Is it performed in a doctor\u2019s office? We wish the story had included some details on this.", "answer": 0}, {"article": "Plenary sessions feature the latest research on the use of and testing for cannabis, combating premature death due to preventable causes such as tobacco and alcohol, the development of an \"intelligent\" surgical knife, programmable bio-nano-chips, and the epigenetic causes of disease.\n\"This fast, accurate testing will allow doctors and patients to make more informed choices earlier to potentially slow the possible progress of Alzheimer's.\"\nResearchers from Randox Laboratories collaborated with research colleagues at the Medical University of Vienna and found that results from the two tests were in 100% agreement.\n\"Pairing this test with medical and family history for risk of Alzheimer's disease has the real potential to advance personalized medicine,\" said Harte.\nTo verify the accuracy of the biochip test, 384 samples were analyzed and results compared to those from a standard molecular diagnostic test.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release should have offered a timetable on availability or next steps in development.", "answer": 0}, {"article": "Many food studies simply lump brown and white rice together.\nBut the Harvard study is one of the first to distinguish between brown rice and white rice consumption in the United States, where rice is not a staple food and relatively little is eaten overall, said Dr. Qi Sun, an instructor in medicine at Brigham and Women\u2019s Hospital, which is affiliated with Harvard Medical School.\nThe researchers tried to control for the fact that Americans who eat brown rice tend to be more healthy overall \u2014 they eat more fruits and vegetables and less red meat and trans fats, and they also tend to be thinner, more active and less likely to smoke than those who don\u2019t eat brown rice.\n\u201cIt\u2019s really recommended to replace white rice with the same amount of brown rice or other whole grains.\u201d\n\nThe researchers who did the study analyzed rice consumption among 39,765 men and 57,463 women who participated in the Health Professionals Follow-up Study and the Nurses\u2019 Health Study I and II; participants in the three groups ranged in age from 26 to 87.\nAnd correlation does not necessarily mean a cause-and-effect relationship, since factors other than brown rice consumption may have accounted for the decreased diabetes risk that was observed.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\u00a0Both white rice and brown rice are widely available. \u00a0That said \u2013 there are food oases where comprehensive grocery stores are not accessible and where brown rice would be more difficult, though not impossible to come by. \u00a0There was no discussion of this in the story.", "answer": 1}, {"article": "Once a woman hits puberty the number drops to 300,000 and by age 30 the amount decreases by 90 percent.\n\u201cI was very career-minded and very focused and had relationships throughout my 20s and early 30s, but still wasn't in that forever relationship.\u201d\n\nWomen are born with a finite number of eggs: they start out with roughly one to two million in their ovaries.\nFor years, it\u2019s been a staple in fertility clinics; it\u2019s officially called the Anti-M\u00fcllerian hormone (AMH) test.\n\u201cIt's a question of having the knowledge and awareness of keeping your options open.\u201d\n\nThe test is a simple blood analysis that usually costs less than $100.\nThe test has traditionally been offered to women who are struggling to get pregnant and helps assess the possible next steps, such as getting pregnant sooner or freezing eggs.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story mentioned the blood test is pretty common in fertility clinics, and we\u2019re informed that the patient in the story took the test at her regular ob/gyn\u2019s office. That\u2019s enough information to give readers\u00a0a general sense of the test\u2019s availability.", "answer": 1}, {"article": "Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities.\n\"This kind of approach to anticoagulation therapy requires an open line of communication between the patient and the care team, and calls for a specific type of patient.\n\"The goal of this study was to find a safe and effected treatment option, and our initial results support 'as-needed' blood thinners and pulse monitoring as the alternative.\"\n\"These are patients who were actively seeking, preparing for and are committed to the alternate treatment method, and who are informed about how to diligently and effectively monitor their pulse throughout the day.\"\nTo determine an alternate but effective therapy, the researchers enrolled 100 patients age 45-78 with significant stroke risk and coupled with diligent pulse monitoring -- manually or by using a smartphone - twice a day with \"as needed\" anticoagulants for the treatment of AF.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It seems obvious that the drugs being studied are on the market and fully available, but it is hard to definitively know this. The news release tells us the drugs are \u201cnovel\u201d but doesn\u2019t name them.", "answer": 0}, {"article": "\"I never expected apple consumption to reduce bad cholesterol to this extent while increasing HDL cholesterol or good cholesterol by about 4 percent,\" Bahram Arjmandi, chair of the department of nutrition, food and exercise sciences at Florida State University in Tallahassee, said in a statement.\nIn fact, they lost an average of 3.3 pounds.\n\"A large reason apples are so good is the fiber.\nInsoluble is found more in the skin, and the pulp is more soluble fiber.\"\nIt's kind of like nature's toothbrush, and it's brushing the bad stuff out,\" she explained.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. The availability of apples is not in question.", "answer": 2}, {"article": "The median survival of those getting surgery and Hipec, plus intravenous chemotherapy, was 22.3 months, almost double the 12.6 months for those getting only the intravenous chemotherapy.\nWhile proponents contend that the risk of dying from the surgery has been reduced since the Dutch trial, the procedure still lasts eight hours or more and full recovery can take three to six months.\nWhile some patients did seem to live much longer than expected, he said that they had been carefully selected and might have fared well even without the therapy.\nThe man\u2019s belly was filled with three liters of saline fluid and the chemotherapy, a generic drug called mitomycin C, heated to 42 degrees Celsius, or nearly 108 degrees Fahrenheit.\nCT scans cannot pick up many of the small tumors, so it is often unclear how much cancer is inside until the patient is opened.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story states that \u201can increasing number of the nation\u2019s leading medical centers has been offering the costly \u2014 and controversial \u2014 therapy to patients with the more common colorectal or ovarian cancers\u201d and names some of them.", "answer": 1}, {"article": "The restrictive diet lasted for five weeks.\nTHURSDAY, Feb. 3, 2011 (HealthDay News) -- A special restrictive diet may significantly reduce symptoms of attention-deficit hyperactivity disorder (ADHD) in young children, a new study suggests.\n\"Since none of the children stayed on the diet beyond five weeks, it is hard to know if this dietary intervention offers sustained benefit,\" he said, adding, \"Since it is more difficult to enforce restricted diets in older children, this approach may not be suitable for the majority of older children with ADHD.\"\n\"We think that dietary intervention should be considered in all children with ADHD, provided parents are willing to follow a diagnostic restricted elimination diet for a five-week period, and provided expert supervision is available,\" they concluded.\n\"If parents have noticed that a child's behavior seems to get worse with certain foods, it may be worth considering,\" said Ghuman, who is an associate professor of psychiatry and pediatrics at the University of Arizona in Tucson.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the diet, allowing readers, especially parents, to understand at least the basics of what it would entail. The problem with both stories, though, was that they did not say anything about food preparation. Is serving a child fried chicken the same as grilled? Are french fries as good as a baked potato? In fairness, the studies that are cited by this study don\u2019t provide good detail on the food preparation, either. There are so many fad diets out there claiming to help children with a range of behavioral disorders that we thought as much guidance as possible would be important. Still, we thought enough detail was presented to warrant a satisfactory rating.\n", "answer": 1}, {"article": "Similar training is an effective component in treating amblyopia, also called \u201clazy eye,\u201d which is the most frequent cause of vision loss in infants and children, affecting 3 percent of the population.\nHowever, other studies with no commercial links obtained similar results, and several scientists I spoke to, including those without ties to GlassesOff, thought the science behind the app was credible.\nReading at our normal pace, the brain has only about 250 milliseconds to do this work until the eyes automatically move onto the next letter or word.\nAfter first taking in \u201craw data\u201d of an image through the eye, different sets of neurons in the brain process it as separate features like edges and colors.\nIt should be acknowledged that some researchers involved in many of these studies have financial ties to GlassesOff.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story notes that various smartphone apps are available that provide this training and that the author picked the only one that had any supporting scientific evidence.", "answer": 1}, {"article": "Leone-Bay said that cancer studies have been conducted on Afrezza in rats.\n\"They have done the required safety studies and come out clean, but it's only been tested for six months, so long-term isn't known,\" said Sanjoy Dutta, director of the insulin initiative at the Juvenile Diabetes Research Foundation.\n\"Afrezza differs a lot from Exubera,\" she said, both in the way it's made and in the way it works.\nCurrently, the only way to get that insulin is through injection or an insulin pump that must be inserted in a new site under the skin every few days.\nTUESDAY, March 23, 2010 (HealthDay News) -- A new form of inhaled insulin appears to help people with diabetes who must use insulin, with fewer potential risks than an earlier form of inhaled insulin that is no longer on the market.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article makes it clear that the product is not approved by the FDA for use at this time.\u00a0It needs to be pointed out that the story makes FDA approval seem like a foregone conclusion. The article is written that way. \"It will only replace meal-time insulin,\" the author writes. No, it\u00a0would\u00a0replace meal-time insulin\u00a0if\u00a0it\u2019s approved. Also, the statement that this therapy would replace meal time insulin is not supported by the evidence. \u00a0The interviewee would lead the reader to believe that meal-time insulin is dangerous, and the evidence would not support this conclusion.", "answer": 1}, {"article": "Newswise \u2014 Faced with the negative quality-of-life effects from surgery and radiation treatments for prostate cancer, low risk patients may instead want to consider active surveillance with their physician, according to a study released Tuesday by the Journal of the American Medical Association (JAMA).\nThe authors also reported that:\n\n- Surgery was associated with fewer urinary irritative symptoms, like weak urine stream or urinary frequency, compared to active surveillance.\n\u201cUrinary incontinence was reported as a moderate or big problem in 14 percent of men three years after surgery compared to 5 percent of men who had radiation,\u201d Barocas said.\nThis is why most doctors recommend \u2018active surveillance\u2019 for low-risk cancers,\u201d he said.\n- Radiation patients had similar urinary irritative symptoms to men on active surveillance, which is an improvement from previous studies with older radiation techniques.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t say so explicitly but it\u2019s generally understood that all the treatments studied are widely available and applied.", "answer": 2}, {"article": "Three years later, researchers continue to detect the presence of the cloned cells they infused into the patient, 61-year-old high school history teacher Gardiner Vinnedge of North Bend, Wash.\n\nFor six years, Vinnedge endured painful rounds of chemotherapy, only to have his melanoma return.\nThis type of \"adoptive immunotherapy\" could be effective against a wide range of cancers, Yee said.\nIt aims to charge up the patient's immune system to attack cancer cells and halt their out-of-control growth.\nThe researchers hoped that by choosing T cells more selectively and cloning only those judged most likely to vanquish their foe, the treatment would be more effective.\nIn six of the 11 patients in the trial, the melanoma stopped progressing for 12 to 19 weeks.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "We think it\u2019s clear from the story that this is only an experimental approach right now.", "answer": 1}, {"article": "Some 68% of the country is either overweight or obese, but there\u2019s not much clinical evidence on the best way to lose weight, outside of research on bariatric surgery. (True, \u201cEat less and exercise more\u201d is great advice if you can manage to follow it, but public-health authorities have repeated that line until they\u2019re blue in the face and as a population we\u2019ve only gotten fatter.)\n\nResearch presented over the weekend at the annual meeting of the Obesity Society and published online in the Journal of the American Medical Association suggests a few specific strategies that may help \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "This is a tricky one. Because the study was funded by Jenny Craig, it seems some mention of how widespread Jenny Criag programs are would have been warranted. Absent that, the story could have said how easy it might be for the typical person to find a diet program of any sourt that would provide people once-weekly face-to-face counseling, which was the regimen that had the best results \u2013 and for free! It might seem obvious that these programs are popping up all over the place, but they are not uniformly available, especially in rural and poor areas in counties that have high concentrations of obesity. If the story had even mentioned how many Jenny Craig centers (according to the company\u2019s website it is 565) we would have given this one a passing grade.", "answer": 0}, {"article": "EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT\nResults of those tests show lab rats that received the cardiosphere-derived cells:\n\u2022 Demonstrated longer heart cell telomeres, compound structures located at the ends of chromosomes that shrink with age\n\u2022 Improved their exercise capacity by an average of approximately 20 percent\n\u2022 Regrew hair faster than rats that didn't receive the cells\n\n\"This study didn't measure whether receiving the cardiosphere-derived cells extended lifespans, so we have a lot more work to do,\" said Lilian Grigorian-Shamagian, MD, PhD, co-primary investigator and the first author of the study.\n\"We have much to study, including whether CDCs need to come from a young donor to have the same rejuvenating effects and whether the extracellular vesicles are able to reproduce all the rejuvenating effects we detect with CDCs.\"\nLOS ANGELES (EMBARGOED UNTIL AUG. 14, 2017, AT 10 A.M. EDT ) - Cardiac stem cell infusions could someday help reverse the aging process in the human heart, making older ones behave younger, according to a new study from the Cedars-Sinai Heart Institute.\nIn the study, investigators injected cardiosphere-derived cells, a specific type of stem cell, from newborn laboratory rats into the hearts of rats with an average age of 22 months, which is considered aged.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a close call. We rate this criterion Satisfactory since the release includes some cautionary language about the availability and applicability of cardiac stem cells, stating that they \u201ccould someday help reverse the aging process in the human heart\u201d and \u201cWe have much to study\u2026\u201d\nHowever, the release also mentions that the cardiac cells \u201chave been used in other human clinical trials,\u201d but doesn\u2019t clarify whether it\u2019s been approved by the FDA for use in humans.", "answer": 1}, {"article": "\"While reductions in [cardiovascular] death still trump these bleeding events, if rivaroxaban is approved, we should expect a number of bleeding events that will require medical attention,\" Hicks wrote.\nXarelto (rivaroxaban) is one of a new class of blood thinners that have been developed to overcome some of the problems that exist with the standard treatment, warfarin (Coumadin), which requires constant dose monitoring.\n\"While it is true that these bleeding events typically do not lead to death or irreversible harm, these events may represent the biggest problem for both patients and health care providers if rivaroxaban is approved.\"\nThe review came in briefing documents that were filed Monday in advance of an FDA advisory panel meeting Wednesday, at which the panel is to vote on whether to recommend approval of Xarelto for treating people with acute coronary syndrome (a group of conditions brought on by sudden reduced blood flow to the heart).\nPeople who took Xarelto -- and suffered from the most common type of atrial fibrillation and didn't have heart valve damage -- were about one-third less likely to experience bleeding in the brain than those who took warfarin, the investigators found.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story explains that the drug is already used for atrial fibrillation and in people having hip or knee replacement surgery.\nAnd with that general availability comes the ability of people to ask for Xarelto and for their physicians to prescribe it without the benefit of seeing the final recommendation from the scientific advisory board or final FDA approval for this new indication.", "answer": 1}, {"article": "Christian\u2019s team studied 676 school-age children whose mothers had been in a clinical trial in which some got iron and folic acid supplements and other nutrients while they were pregnant.\nCHICAGO (Reuters) - Children in rural Nepal whose mothers were given iron and folic acid supplements during pregnancy were smarter, more organized and had better fine motor skills than children whose mothers did not get them, U.S. researchers said on Tuesday.\n\u201cIron is essential for the development of the central nervous system,\u201d said Parul Christian, an expert in international health at the Johns Hopkins University Bloomberg School of Public Health, whose study appears in the Journal of the American Medical Association.\nIron deficiency is the most common and widespread nutritional disorder in the world, affecting 2 billion people, according to the World Health Organization.\nThe World Health Organization estimates that in developing countries, every other pregnant woman is anemic and about 40 percent of preschool children are anemic.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "One assumes that iron and folic acid supplements are widely available, but this may not be the case in some countries. There wouldn\u2019t be a need for this sort of intervention if these nutrients were part of the regular diet in Nepal and other countries. At least some nod to how hard it might be to get access to these supplements was warranted.\u00a0It also would have been helpful to include information about whether any existing public health programs routinely supplement with iron and folic acid in developing countries.", "answer": 0}, {"article": "Atrial fibrillation also increases the risk for dementia.\nHowever, the findings show that people with atrial fibrillation should start taking blood thinners as soon as possible after their diagnosis and continue to take the drugs, Friberg noted.\nThe findings strongly suggest that blood thinners reduce the risk for dementia in people with atrial fibrillation, but proving that would not be possible, the Swedish researchers said.\nAt the time they joined the study, about half of the participants were taking oral anticoagulants, such as warfarin, Eliquis (apixaban), Pradaxa (dabigatran), Savaysa (edoxaban) or Xarelto (rivaroxaban).\nBecause atrial fibrillation increases the risk for stroke, people with the condition are often prescribed blood thinners (also known as anticoagulants) to prevent blood clots that can cause a stroke.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It may seem fairly obvious that these anticoagulants are widely prescribed.\u00a0 The fact that the study was among community-dwelling people who were already taking these treatments reinforces their availability.", "answer": 1}, {"article": "WEDNESDAY, April 4, 2012 (HealthDay News) -- Regularly consumption of food and drink rich in substances called flavonoids, such as berries, apples, tea and red wine, can lower a man's risk of developing Parkinson's disease by 40 percent, new research suggests.\nPeople can include berries in their regular diet.\n\"Berries could be a neuroprotective agent.\nResults of the study are published online April 4 in the journal Neurology.\nAnthocyanins are a type of flavonoid plentiful in such berries as strawberries and blueberries.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of these foods is not in question.", "answer": 2}, {"article": "\"Experimental studies suggest that fructans may be beneficial in diabetes, obesity, stimulating the immune system of the body, decreasing levels of disease-causing bacteria in the intestine, relieving constipation and reducing the risk of colon cancer,\" Mercedes Lopez, of the National Polytechnic Institute in Guanajuato, said in the news release.\nThe fructans turn into alcohol when agave is processed into tequila, they said.\n\"They can be used in many products for children and infants to help prevent various diseases, and can even be used in ice cream as a sugar substitute.\"\nBut drinking tequila won't help, the study authors noted.\nCompared to other mice, those fed agave fructans absorbed more calcium from food, excreted less calcium in their feces, and had a 50 percent increase in levels of a protein associated with the build-up of new bone tissue.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable.\u00a0 The availability of these plants is not in question. ", "answer": 2}, {"article": "Papa and her team expanded on that work by studying how levels of these two proteins, or biomarkers, change immediately after head trauma.\nEven at that point, the study shows, GFAP levels might be higher than normal and therefore might indicate TBI and need for further tests.\nGFAP, which is specific to cells known as astrocytes that form a matrix for nerves in the central nervous system (which includes the brain and spinal cord), peak at 20 hours after the injury and then decline steadily but are still detectable seven days later.\nThere\u2019s growing evidence that concussions may have more lasting effects than previously thought, and that monitoring people with head injuries, no matter how apparently minor, is crucial to ensuring they receive proper treatment and minimize the effects of the trauma.\nBut in a study published in , scientists report on a promising blood test that could distinguish the more serious cases of TBI that require further evaluation.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story implies these tests aren\u2019t yet available, chiefly by calling them \u201cpromising.\u201d However, the story should have made it explicitly clear whether these tests are something patients could ask for now.", "answer": 0}, {"article": "PhD candidate Alexandra Wade says the new MedDairy diet challenges popular perceptions of what is considered healthy.\n\u201cThe new MedDairy diet allows for three to four servings with dairy, which means Australians can more sustainably meet their recommended daily nutrient intakes while also maintaining the significant health benefits offered through the MedDiet.\nIt also includes 1-2 servings of dairy foods (700-820mg calcium), which is less than half the dairy recommended by the Australian National Health and Medical Research Council (NHMRC) for older Australians.\nThe results show that the dairy-supplemented MedDiet (MedDairy) significantly improved blood pressure, heart rate, cholesterol, mood and cognitive function.\nIn this UniSA study, published by the American Journal of Clinical Nutrition, researchers compared the health benefits of a MedDiet supplemented with two to three serves of dairy each day, and a generic low-fat diet.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Although the news release doesn\u2019t discuss availability, it\u2019s generally understood that items for a dairy-supplemented Mediterranean diet can likely be found in many grocery stores.", "answer": 2}, {"article": "In another study released during the Wednesday press conference, researchers from M.D.\nThat recommendation met with outrage from breast cancer specialists, while other organizations, including the American Cancer Society, continued to recommend annual mammograms for women in their 40s.\nLast year, the U.S. Preventive Services Task Force recommended that women in their 40s not at high risk for breast cancer could forego mammograms until they turned 50 and, even then, it said they only needed to undergo screening once every two years.\nThe findings will no doubt do little to quell a controversy that has existed since the 1980s over the value of mammography screenings for women in their 40s.\nWhile the optimal schedule of regular mammograms continues to be discussed by experts in the field, the critical message here is that all women starting at age 40 should talk to their doctor to understand the benefits and risks of screening and to understand what is best.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not discuss availability of mammography, but such availability is really not in question.\u00a0 So this is judged not applicable because we can\u2019t give it a satisfactory or an unsatisfactory score. ", "answer": 2}, {"article": "The U.S. National Institute of Arthritis and Musculoskeletal and Skin Diseases has more about hip replacement.\nRheumatoid arthritis affects about 1.3 million people in the United States, while osteoarthritis affects 27 million Americans aged 25 and older, according to the American College of Rheumatology.\n\"Joint arthroplasty is successful in relieving the pain and disability caused by hip or knee arthritis,\" study author Dr. Bheeshma Ravi, from the University of Toronto and Women's College Research Institute, said in a journal news release.\nThe study team found no differences between the two groups of arthritis patients in rates of follow-up surgery, or 90-day blood clot or death risk.\nWEDNESDAY, Nov. 28, 2012 (HealthDay News) -- Patients with rheumatoid arthritis are more likely to suffer hip dislocation after hip replacement surgery than those with osteoarthritis, a new study says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Not applicable. No details were given about the availability or widespread use of joint replacements.\u00a0 Even though no specific numbers are reported, readers should understand that joint replacement is a widely available treatment.", "answer": 2}, {"article": "May 4, 2010 (New York) -- An experimental weight loss/blood pressure pill may pack a one-two punch against hunger and high blood pressure, one of the main health consequences of obesity, according to new research presented at the American Society of Hypertension\u2019s 25th annual meeting in New York.\nThe higher the dose, the more substantial the weight loss, and the more likely it was to be maintained over time, the study shows.\nThe new analysis of three separate studies included more than 4,500 people.\nData on this drug are slated to be reviewed this summer by an FDA advisory panel.\nAt six months, people who took the full dose of Qnexa once daily lost nearly 10% of their body weight; by one year, it was up to 10.4%.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s pretty clear from the story that the combination of the two drugs is not yet available. ", "answer": 1}, {"article": "A widely anticipated study suggests that hormone therapy started soon after menopause can ease depression, anxiety, hot flashes and other adverse symptoms that many women face, without increasing risks for cardiovascular disease.\n\nThere was no increase in breast cancer, stroke, heart attack or blood clots, but the study's researchers said the sample size was too small and the study time too short to draw firm conclusions.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It is general knowledge that estrogen and progesterone hormone therapies are common and widely available. The story cited some data on the decline in estrogen and progesterone use in the US.\n\u00a0", "answer": 1}, {"article": "Dry air can also exacerbate some illnesses and can be a problem as well.\u201d\n\nDifferent sources of air pollution in your home could include paints that release lead or volatile organic compounds (VOCs), carpets that harbor dirt, dust mites, and fungus and even nitrogen dioxide from gas stoves, but these aren\u2019t the worst culprits, Lahita said.\n\u201cThe goal for the user is to keep five green dots.\nThe device collects data such as indoor temperature, humidity, carbon dioxide, fine dust particles and VOCs.\nBased on your air score, the monitoring gadget will send personalized alerts and advice to the user via its corresponding Awair mobile app.\nFor more information go to GetAwair.com.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that the device and app are already available.", "answer": 1}, {"article": "As a result of the review, the team say their study highlights the need for randomised trials to establish the evidence needed to support low-dose aspirin as an effective additional treatment of cancer.\nThe study identified five healthy behaviours as being integral to having the best chance of leading a disease-free lifestyle: taking regular exercise, non-smoking, a healthy bodyweight, a healthy diet and a low alcohol intake.\nThat's why we specifically looked at the available evidence of bleeding and we wrote to all authors asking for further data.\nIn no study was serious or life-threatening bleeding reported.\"\nAs a result, we set out to conduct a systematic search of all the scientific literature.\"\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release doesn\u2019t address availability but we know aspirin is available in pretty much any convenience store on Earth. We\u2019ll rate this \u201cnot applicable.\u201d", "answer": 2}, {"article": "Type 2 diabetes is caused by the body\u2019s in ability to break down sugars from the diet.\n\u201cIt isn\u2019t an irreversible, inexorable condition that you can never escape from \u2014 at the moment, people are told that.\u201d\n\nPrevious studies have suggested that lifestyle changes, including diet and exercise, can be powerful ways to lose weight and combat diabetes.\nThe diet, which was designed to help people lose up to 30 pounds, involved three to five months of a strict low-calorie liquid formula diet averaging no more than 850 calories a day, followed by two to eight weeks of reintroducing food, along with nutritional education and cognitive behavioral therapy to help people stick with the new eating plan.\nIn the study, Dr. Roy Taylor, professor of medicine and metabolism at Newcastle University, and his colleagues randomly assigned nearly 300 people to either a weight management program or their usual treatments, including diabetes medications.\nTaylor stresses that the study only addressed people diagnosed relatively recently \u2014 within the past six years \u2014 and that the effect may not apply to more long-term patients.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story outlines the components of the diet, but not whether an interested could access such care from a physician. Given the extremeness of the diet \u2014 the first months are limited to 850 calories a day and education and therapy adjuncts are brought in to help people maintain their progress when switching from the liquid nutrition to real food, not to mention a mountain of evidence on the difficulty of maintaining weight loss \u2014 it seems likely that health care providers\u2019 help would be necessary.", "answer": 0}, {"article": "For more information about the AACR, visit http://www.\n\"The results of the trial supported the FDA decision to grant breakthrough therapy designation to abemaciclib (previously known as LY2835219) for patients with refractory hormone receptor-positive advanced or metastatic breast cancer,\" added Patnaik.\nAmong the 36 patients with hormone receptor-positive breast cancer, 11 had a partial response, with four of the 11 responders having continued prior endocrine therapy, and an additional 18 patients had stable disease.\nAuthor Comment: \"These data show that abemaciclib is an oral drug that can be taken on a continuous schedule and achieve durable clinical activity against multiple tumors including breast and lung cancers,\" said Shapiro.\nFor example, abemaciclib has greater selectivity for CDK4 compared with palbociclib, which may explain why it does not affect white blood cell counts as severely, allowing it to be taken on a continuous schedule without treatment holidays, he said.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that abemaciclib is now being tested in trials designed to \u201cdefine the role of abemaciclib in cancer care.\u201d However, it never explicitly states that these trials might end up finding that the drug does not ultimately provide sufficient advantages over existing treatments. Its reference to \u201cinvestigational\u201d in the title and text may be enough to give some readers the tip-off that this drug won\u2019t be available anytime soon. However, we recommend news release writers make it abundantly clear when a drug is only available as part of research trials and that it is not available for use in routine clinical practice. The statement, \u201cFDA decision to grant breakthrough therapy designation,\u201d may lead a reader to think this could be available for use more broadly.", "answer": 1}, {"article": "No more than a few days later, the samples were transported to labs at the university, where they remained frozen until they were processed by researchers. This ensured that none of the bacteria had a chance to grow or change from the time the sample was collected. Also, it guaranteed that all samples were treated the same way.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Same comment as the \u201cCompare Alternatives\u201d section.", "answer": 2}, {"article": "The requested URL /usnews/health/articles/070506/14healthwatch.lede.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story does not mention if the intravenous (IV) zoledronic acid (Reclast) has been FDA approved or whether it is available or not.", "answer": 0}, {"article": "The Heart Association also stressed that three-quarters of sudden cardiac arrest cases outside the hospital occur in the home.\nThat hesitation is rooted not only in reluctance to lock lips with a stranger, but by anxiety over how to perform conventional CPR, in which the rescuer breathes into the victim twice after every 30 chest compressions.\n\"If you have access to an AED (Automated External Defibrillator), you want to apply that as early as possible,\" advised San Francisco General's Barton.\n\"We think that if we can double the number of bystanders who attempt CPR, we can save tens of thousands of lives every year,\" said Mary Fran Hazinski, a nurse at Vanderbilt University Medical Center and spokeswoman for the American Heart Association.\nTwo years ago, after considering multiple studies, the Heart Association recommended hands-only CPR only in cases where people were unwilling or unable to provide the rescue breaths as well.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The news article makes it clear that virtually anyone can perform hands-only cardiopulmonary resuscitation (CPR). It requires no devices or drugs. The major barrier to treatment appears to be fear\u2013of harm to the victim or rescuer, and/or and fear of failing to perform CPR correctly.", "answer": 1}, {"article": "Newswise \u2014 Omega-3 fatty acids may lower the risk of breast cancer in postmenopausal obese women, according to researchers.\nThe researchers plan to test the effect of DHA alone in obese subjects, potentially in combination with weight loss, in a future trial.\nAt the conclusion of the two-year study, the researchers found that increasing levels of omega-3 in the blood were associated with reduced breast density\u2014but only in women with a body mass index above 29, bordering on obesity.\nAlthough Lovaza contains both of the fatty acids DHA -- 375 milligrams -- and EPA -- 465 milligrams, only DHA blood levels were associated with breast density reduction.\nSome epidemiological data supports the idea that omega-3s protect against breast cancer, but the findings have been inconsistent.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The release notes that the omega-3 fatty acid supplement used in this study, Lovaza, is FDA approved and requires a prescription from a physician.", "answer": 1}, {"article": "\"All clinical trials to date have failed due to side effects ranging from stroke, skin fibrosis and cardiovascular issues.\n\"Our compound only locks the collagen -degrading CatK activity, preventing the unregulated breakdown of collagen in bones without any other negative impacts.\"\nWe've found a way to block CatK only in bone tissue that we think will prevent these other negative effects.\"\nUsing a compound derived from red sage, UBC researchers have found a way to selectively block an enzyme called Cathepsin K (CatK), which plays a major role in the breakdown of collagen in bones during osteoporosis.\nAn herb widely used in traditional Chinese medicine might hold the key to a new osteoporosis therapy that could prevent bone loss without causing side effects.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The news release says the red sage is \u201cwidely used\u201d in traditional Chinese medicine. That conveys that it\u2019s easy to get.", "answer": 1}, {"article": "The requested URL /usnews/health/articles/070513/21sunscreen.htm was not found on this server.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story focuses largely on the increasing availability of new sunscreen formulations that are believed to protect sun lovers from harmful ultraviolet rays.", "answer": 1}, {"article": "An experimental drug designed by Roche Holding AG's Genentech unit against a new cancer target yielded encouraging results against two rare tumors, researchers said, potentially opening up a new front in the battle against the disease.\n\nIn a small study, the drug, known as GDC-0449, shrank tumors in 18 of 33 patients, or 55%, with an advanced form of a skin cancer called basal cell carcinoma. In addition, the drug had a dramatic, though temporary, effect on a 26-year-old patient who had undergone multiple surgeries, chemotherapy...", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story makes it clear that this drug is still in the experimental phase and the FDA has not yet approved it.\u00a0 ", "answer": 1}, {"article": "\"I think [the results] are very encouraging,\" Bruce Lanser, a pediatric allergist who directs the Pediatric Food Allergy Program at National Jewish Health in Denver, told us.\nSo, if you or your child tested positive for a food allergy years ago, you may want to consider seeing an allergist again.\nNow, a new study sheds light on the effectiveness of a test called a food challenge to determine whether a person can tolerate a food they once reacted to.\nThe blood test measures the levels of a certain type of antibody, immunoglobulin E (IgE).\nHe says many of the patients in the study may have outgrown their allergy, just like Jula did.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story doesn\u2019t discuss how easy it is to find an allergy clinic that does oral food challenges, but it does refer parents to allergists for further discussion.", "answer": 1}, {"article": "The studies also varied in quality, with only nine of 26 considered \"low [in] bias,\" according to background information accompanying the study.\nThe analyses indicated that SMT -- which involves manual manipulation of the spine and surrounding muscles -- has only a short-term impact on pain relief, although it eases pain faster than other treatments.\nWhile chiropractors often perform SMT on patients, it is also administered by physical therapists and osteopaths.\nBut which treatment is right for any patient depends not only on their specific pain, but their doctor's recommendations and their own comfort level with various options, said Stephen Perle, a spokesman for the American Chiropractic Association.\nReviewing 26 studies comparing spinal manipulative therapy (SMT) to other treatments such as medication, exercise or physical therapy, researchers from the Netherlands found that SMT appears to be no better or worse than other options at relieving back pain long-term.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article gets a \u201csatisfactory\u201d because it pointed out that manipulation is commonly performed by multiple healthcare professions. \u00a0It would have been useful to mention that manipulation is not routinely available in conventional primary care medical settings.\u00a0 And despite its evidence record, it does not generally enjoy completely consistent insurance coverage.\u00a0 The same points apply to massage.\n \n", "answer": 1}, {"article": "About 10 percent of the students had an abnormal EKG.\nThe severity of this and the other two problems that turned up as a result of the abnormal EKGs are reason enough, Debauche says, to screen all school athletes nationwide.\n\"It's pretty much while they're in training or while they're on the field performing, because that's when the adrenalin is flowing,\" and that's when they're calling on the heart for peak performance.\nThe American Heart Association suggests that athletes who are identified as at risk for heart problems as a result of a family history or physical exam be referred for further cardiovascular examination, which could include an electrocardiogram.\nAccording to Zipes, \"The adrenalin that is released when you're participating [in sports] can stimulate this abnormally thick heart muscle and cause a fatal heart rhythm problem, that is a very rapid heartbeat with no effective contraction, no blood being ejected to the brain and other organs.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "1clip_filelist.xml\" rel=\"File-List\"/>1clip_themedata.thmx\" rel=\"themeData\"/>1clip_colorschememapping.xml\" rel=\"colorSchemeMapping\"/>\n\n\n\n\nThe story states that electrocardiograms are not provided to all student athletes prior to participation in sports. Although it satisfies the minimum standard for a satisfactory rating on this criterion, the story could have done a better job in explaining that heart screening for student athletes (including EKG) is routinely available and relatively easy to obtain. A brief description of the way in which an EKG is obtained would have provided some context for the reader. \n", "answer": 1}, {"article": "After reviewing the data, the committee concluded that the evidence for the benefits of high levels of vitamin D was \u201cinconsistent and/or conflicting and did not demonstrate causality.\u201d\n\nEvidence also suggests that high levels of vitamin D can increase the risks for fractures and the overall death rate and can raise the risk for other diseases.\nNot only is it in orange juice and milk, but more is being added to breakfast cereals, and it now can be found in very high doses in supplement pills.\nVitamin D is more complicated, the group said.\nWith calcium, adolescent girls may be the only group that is getting too little, the panel found.\nThe American Society for Bone and Mineral Research and other groups applauded the report.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of vitamin D from diet, sunlight and supplements is clear from the story.", "answer": 1}, {"article": "While some studies have shown promise, he says, \u201cthe quality of the evidence is not strong.\u201d That\u2019s why Briggs and his colleagues are starting a study looking at dry needling in \u201crunner\u2019s knee,\u201d the condition that has plagued Pierce.\nAnother possibility: It\u2019s a placebo effect, an improvement triggered by the expectation that a treatment will work rather than by the treatment itself.\nIt\u2019s called \"dry needling,\" and it involves the insertion of thin, non-medicated solid needles into muscles or connective tissues.\nAnd most of the nation\u2019s 200,000 licensed physical therapists are not trained in the technique.\nAbout 6,000 have taken courses in dry needling in the past few years, Zylstra says.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story essentially lets people know that this is something that is becoming more popular but that not very many physical therapists are trained in it yet.", "answer": 1}, {"article": "And AbbeVie is in the midst of phase 3 trials for elagolix to treat uterine fibroids and endometriosis, a disorder in which the tissue that lines the inside of the uterus grows outside of it, causing pelvic pain.\nThe first oral treatment for women with the common condition of uterine fibroids could be available as soon as summer 2018, with two other medications in the pipeline.\nThe cause of fibroids remains unknown, though those with a family history have an increased risk of developing them.\nIt\u2019s estimated that as many as 26 million women in the U.S. have one or more such tumors, though less than half experience symptoms.\nThe most common symptom is long and excessive bleeding during menstrual periods, which can lead to anemia and the need for blood transfusions.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The article notes the new drug could be available in the US next year. The drug is already available in the US for another indication but is packaged in doses that are much larger than those used for fibroid treatments.", "answer": 1}, {"article": "\u201cDoctors and patients need to think about the cancer risk when ordering this test.\u201d\n\nThe study, published in the new edition of Archives of Internal Medicine, found a small but real risk from the average radiation \u2014 for every 100,000 men between 45 and 75 undergoing the test every five years, there would be 42 cancers; for every 100,000 women ages 55 to 75, there would be 62.\nThey say the test's value is limited because it doesn't identify which plaque are stable and which could rupture and cause a heart attack.\nOne Houston doctor said that there was just one scanner in Houston in the mid-'90s, and now the $1 million machines are all over the city.\nThe Texas law will require insurance companies pay $200 of the bill for patients to get the test every five years.\nHe questioned unsupported cutoffs of those covered under the law and said it would have been better to wait until more data is available on who really benefits from it.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe story says that the CT scanners used for this test are \u201call over the city\u201d and included an estimate that in 2008 about 200,000 people around the country were scanned for calcium buildups in their coronary arteries.", "answer": 1}, {"article": "But such drugs tend to be extremely expensive.\nScaling up the procedure should make it even less expensive, he said, but he added, \u201cOur costs do not include any profit margin, facility depreciation costs or other clinical care costs, and other research costs.\u201d\n\nThe research is still in its early stages, and many questions remain.\nShe woke up a week later, on May 2, the day she turned 7; the intensive-care staff sang\n\nSince then, the research team has used the same drug, tocilizumab, in several other patients.\nHerv\u00e9 Hoppenot, the president of Novartis Oncology, called the research \u201cfantastic\u201d and said it had the potential \u2014 if the early results held up \u2014 to revolutionize the treatment of leukemia and related blood cancers.\nDespite the mixed results, cancer experts not involved with the research say it has tremendous promise, because even in this early phase of testing it has worked in seemingly hopeless cases.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear that this treatment is not widely available and won\u2019t be any time soon. As a service to patients and parents who might be in desperate straits, the story could have provided some information about research plans for the experimental treatment and the possibility (or lack thereof) of enrolling in a study.", "answer": 1}, {"article": "A large, new study may be reassuring to women considering mastectomies because of a history of breast cancer in their families.\n\nStanford University researchers affirmed that women with mothers and sisters who carry one of the BRCA gene mutations but who aren't carriers themselves don't have an especially heightened risk of breast cancer.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the story that BRCA testing is available to women who want it.", "answer": 1}, {"article": "See original publication for details.\nUntil now, prophylactic surgery is the only procedure which significantly reduces the breast cancer risk, but which is also often associated with postoperative complications.\nIn 2010, Josef Penninger, the scientific director of IMBA in Vienna and his team have shown that sex hormones can trigger breast cancer (Schramek et al., Nature) through proteins called RANKL and its receptor RANK, which are key factors in bone metabolism.\nMoreover, the scientists \u2013 together with colleagues in Barcelona and from the CIMBA* consortium mapping more than 23,000 women \u2013 showed that genetic variants in the RANK gene are associated with a higher risk of developing breast cancer in women who carry BRCA1 and also BRCA2 mutations.\nBased on our discovery, the already approved drug Denosumab or other future drugs that will block RANKL/RANK, could be used for breast cancer prevention in BRCA mutation carriers,\" explains Verena Sigl.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "Denosumab has been on the U.S. market as an approved treatment for certain types of osteoporosis since 2010 and tumors since 2013 but it is not approved as a preventative breast cancer treatment. The release may be misleading readers by suggesting it is \u201calready approved.\u201d\u00a0 The completion of safety and efficacy trials in humans are years down the road. The release doesn\u2019t even say that advanced trials are planned, only that they\u2019re \u201cneeded.\u201d", "answer": 0}, {"article": "# # #\nHF10 therapy remained more effective than traditional SCS over the 12 month study period.\nOf these, 90 patients received HF10 therapy, while 81 patients had traditional SCS.\nFor more information on the field of anesthesiology, visit the American Society of Anesthesiologists online at asahq.org.\nThe new treatment, called HF10\u2122 therapy, uses proprietary high frequency pulses of 10,000 Hz, compared to traditional SCS which uses frequencies of 40 to 60 Hz.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s not clear from the release if this device is approved and available. It appears that it is.", "answer": 0}, {"article": "Ralph Sacco and Tatjana Rundek of the University of Miami in an accompanying editorial.\nThe findings, reported in the New England Journal of Medicine, are more evidence of the benefits of sending someone to a hospital even if muscle weakness or slurred speech has only lasted for a few seconds, lead author Dr. Pierre Amarenco of Bichat Hospital in Paris told Reuters Health by phone.\nBut in the new study, Amarenco and his colleagues found stroke risks of 1.5 percent at two days, 2.1 percent at seven days and 3.7 percent at 90 days when mini-strokes were treated aggressively.\nThe researchers also found that the one-year stroke risk doubled when multiple blood vessel clogs were seen with brain imaging, a large artery was narrowed by heart disease and the patient scored a 6 or 7 on a seven-point scale that assesses stroke risk factors.\nThe ongoing study, which used previous stroke estimates for comparison, was based on data from 4,789 patients from TIAregistry.org, an international registry designed to follow cases for as long as five years.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story quotes from the NEJM editorial, which says \u201cthe widespread, systematic implementation of specialized TIA units across multiple sites, countries, and continents can make a difference in the care of these patients.\u201d\nHowever, it\u2019s not clear how common these specialized TIA units are. Can they be found in any major hospital? Only in big cities or especially large medical centers? Only in a few of those medical centers? And is the \u201caggressive\u201d treatment mentioned in the headline only available at these specialized TIA units, or can it be found in most emergency rooms? Readers are left in the dark on this one.", "answer": 0}, {"article": "The new awards provide up to $600,000 each over three years to support the work of collab...\n\nUW to test using MDMA to treat PTSD\n\nThe Department of Family Medicine and Community Health of the UW School of Medicine and Public Health will take part in a multisite Food and Drug Administration-approved Phase III trial investigating MDMA as an adjunct to psychotherapy for the tre...\nThe search committee for the Science and Medicine Graduate Research Scholars (SciMed) program director position enthusiastically announces four finalists who have been invited to give public presentations.\nView a new year's message from Dean Golden for 2019\n\nPlease take a moment to watch a special message from Robert N. Golden, MD, dean of the University of Wisconsin School of Medicine and Public Health, in which he reflects on 2018 and looks ahead to 2019.\nThomas Mackie to lead new joint innovation initiative between UW Health and School of Medicine and Public Health\n\nUW Health has selected Thomas \u201cRock\u201d Mackie to be the inaugural leader of the health system\u2019s innovation initiative, which it is pursuing in partnership with the UW School of Medicine and Public Health.\nRyan Coller wins federal challenge for app to help children with complex care needs\n\nA team of researchers at the University of Wisconsin School of Medicine and Public Health and the College of Engineering have won a share of a $100,000 award to develop technology for families caring at home for children with complex medical needs...\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s clear from the release that both medications in this combination therapy (AChEI and Lupron) are currently available. We appreciate that the\u00a0news release\u00a0ends by noting the preliminary nature of the findings, and the uncertainty as to whether additional studies of this combination will be conducted. But unfortunately, the release\u2019s mischaracterization of the results will likely overpower this note of caution.", "answer": 1}, {"article": "(CNN) -- Taking dietary supplements containing essential fatty acids can help reduce the symptoms of premenstrual syndrome, according to the results of study by researchers at a Brazilian university.\nEssential fatty acids are substances that are not produced by the human body and are only available from diet.\nThe study cites research dating back to 1983 examining such a possible link.\nEggs, nuts, vegetable oils and fish are examples of foods that provide such acids, which are also available in supplement form.\nAccording to the study, women who took the supplements for six months saw a bigger benefit than those who took them for three months.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story described the availability of essential fatty acids in diet and in supplement form.", "answer": 1}, {"article": "It's not something a human can do.\nWhile the study findings indicate that there is a consistent signal present in circulating blood cells of children with spastic CP that remains from early childhood to the teenage years, the researchers say they need to further study samples from different age groups, including teenagers, toddlers, and infants from birth to 2 years.\nIn fact, there is no national surveillance here, but the CDC estimates that 1 in 323 American children have the condition.\n\"Many issues will need to be addressed, but we predict routine screening for CP in the near (<10 years) future,\" he said.\nThe researchers identified a strong set of methylation markers, or patterns, that indicate differences in the genome between children with spastic CP and those without it.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "This was a small pilot study and the release states, \u201cMany issues will need to be addressed, but we predict routine screening for CP in the near (<10 years) future.\u201d\u00a0 While many may differ with whether the \u201cnear future\u201d is define by \u201cfewer than 10 years,\u201d the release gets credit for spelling this out.", "answer": 1}, {"article": "In investigating how BCG administration produces its beneficial effects, the research team identified a mechanism never previously seen in humans in response to treatment with any drug - a shifting of the process of glucose metabolism from oxidative phosphorylation, the most common pathway by which cells convert glucose into energy, to aerobic glycolysis, a process that involves significantly greater glucose consumption by cells.\nIn August 2017 the MGH was once again named to the Honor Roll in the U.S. News & World Report list of \"America's Best Hospitals.\"\nThe researchers also found that BCG could reduce blood sugar elevations in mice that were caused by means other than autoimmune attack, raising the possibility that BCG vaccines could also be beneficial against type 2 diabetes.\nInitial clinical trial results, published in a 2012 PLOS One paper, reported that two doses of BCG spaced four weeks apart led to reductions in autoreactive T cells, an increase in Tregs and what turned out to be a transient increase in insulin production.\nThat reduction was maintained over the next four years, with treated participants having an average HbA1c of 6.65, close to the 6.5 considered the threshold for diabetes diagnosis, and with no reports of severe hypoglycemia.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "It\u2019s mentioned that BCG has been used for \u201calmost a century\u201d to prevent tuberculosis.\n(Of note, it\u2019s also been used for non-invasive bladder cancer.)", "answer": 1}, {"article": "In this case, the study addressed a tricky problem.\nThe women on low-fat diets had a 9 percent lower rate of breast cancer; the incidence was 42 per thousand per year in women in the low-fat diet group, compared with 45 per thousand per year in women consuming their regular diet.\nThe diet they were told to follow \"is different than the way most people eat,\" Dr. Chlebowski said.\nBut the current study, asking if a low-fat diet could protect women from breast cancer in the first place, had findings that fell short of statistical significance, meaning they could have occurred by chance.\n\"The studies were well designed,\" Dr. Freedman said, \"and the investigators tried to confirm popular hypotheses about the protective effect of diet against three major diseases in women.\"\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story failed to point out how the study goals were different than the existing FDA dietary guidelines. FDA calls for percentage of calories from fat (20-35%) with saturated fat (< 10%) and trans fats (limited intake) as compared to the study goals of less than 20% of calories from fat with no target set for either saturated or trans fats. Why were the study goals different than federal agency guidelines? The audience should be told. ", "answer": 0}, {"article": "It's very exciting.\"\nScientists have transformed one type of fully developed adult cell directly into another inside a living animal, a startling advance that could lead to cures for a variety of illnesses and sidestep the political and ethical quagmires\n\nThrough a series of painstaking experiments involving mice, the Harvard biologists pinpointed three crucial molecular switches that, when flipped, completely convert a common cell in the pancreas into the more precious insulin-producing ones that diabetics need to survive.\nThe work was hailed as a welcome development even by critics of research involving embryonic stem cells, which can be coaxed to become any tissue in the body but are highly controversial because they are obtained by destroying embryos.\nThe experiments, detailed online yesterday in the journal Nature, raise the prospect that patients suffering from not only diabetes but also heart disease, strokes and many other ailments could eventually have some of their cells reprogrammed to cure their afflictions without the need for drugs, transplants or other therapies.\n\"I'm stunned,\" said Robert Lanza, chief scientific officer of Advanced Cell Technology in Worcester, Mass., a developer of stem cell therapies.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "While the story was clear that this highly experimental approach in mice is currently not available for humans, it provided a wholly unrealistic estimate for its application to human disease. \u00a0\nAlthough interesting from a number of perspectives, the story is about a novel but relatively untested approach to managing diabetes in mice. \u00a0The story is somewhat excessive in its language related to the potential for this approach suggesting the line of research will indeed be transferable to humans in a relatively brief period of time. While some caveats are included, we don\u2019t think balance was achieved.\u00a0 ", "answer": 0}, {"article": "Researchers assessed the level of cortisol in the hair of 70 nine-year-old children from primary schools across Victoria.\n\u201cLooking at hair tells us new things.\u201d\n\nThe research is part of the ongoing Murdoch Childrens Research Institute\u2019s Childhood to Adolescence Study following a cohort of 1,200 children in and around Melbourne and was published in the journal, Psychoneuroendocrinology.\n\u201cWhat\u2019s less commonly understood is that beyond poor mental health, it can also be associated with the development of other illnesses such as diabetes, obesity and cholesterol issues, because cortisol is also central to glucose availability, blood pressure and immune function, so identifying these children is important.\u201d\n\nWhile blood or saliva tests could be used to detect cortisol levels, these methods were sometimes problematic, especially in children, Simmons said.\n\u201cHowever, hair samples are not only easier to obtain, but provide us with a picture of total cortisol throughout the system across many months rather than just at a point in time,\u201d Simmons said.\nIt suggests hair cortisol levels may provide a marker of trauma exposure in children and identify those at risk of developing psychosocial and behavioural problems, and who may need medical and psychological support, leader of the study and a fellow in child and adolescent mental health at the University of Melbourne, Dr Julian Simmons, said.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Again, since the story speculates aggressively about the clinical usefulness of this test, we\u2019d like to see some information about how widely available it is. Is this a highly specialized test available only to researchers? Could consumers request such tests from any lab? Such context is important to help readers understand the impact of this research.", "answer": 0}, {"article": "The Ache: The bathroom scale shows how much you\u2019ve gained or lost in pounds, but gives no information about whether the change is fat or muscle.\n\nThe Claim: A whole-body scan, called Dual-Energy X-ray Absorptiometry, or DXA for short, gives a detailed snapshot of your body composition, including how your body weight breaks down into fat, bone and lean tissue.", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "Tough call here. The story says that DXA scans are \u201cavailable at a growing number of spas, hospitals and doctor\u2019s offices.\u201d But the statement comes from a company representative. What does \u201cgrowing number\u201d mean? Are you likely to be able to find this outside of posh resorts and major cities?", "answer": 0}, {"article": "For more information, visit www.aao.org.\nThe authors noted the device could also be used for non-glaucoma medications, with potential applications for dry eye, allergies and inflammation.\nAuthors said the device was well-tolerated and safe, with a high retention rate of 89 percent for both groups at six months.\nIn addition, the non-invasive nature of the device and its relatively large surface area make this technology a potential candidate for delivering multiple ocular drugs at once, further reducing the burden of self-administration on patients.\nFor more information on glaucoma, visit the American Academy of Ophthalmology's EyeSmart\u00ae public information website, www.aao.org/eye-health.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The new release accurately states says the device \u201cmay one day be a promising option\u201d for patients who struggle with administering eye drops, though it could give readers a better sense of just how far off that day might be. The news release says a phase 3 trial of larger groups of patients is expected to begin this year, but does explain how long that would take or mention the lengthy process required to win approval from the Food and Drug Administration.", "answer": 1}, {"article": "LOS ANGELES - The supplement Aged Garlic Extract can reverse the buildup of deadly plaque in arteries and help prevent the progression of heart disease, according to a new study scheduled for publication in the Journal of Nutrition.\nDr. Budoff also has received honoraria from Wakunaga.\nIt also educates young scientists and provides community services, including prenatal counseling and childhood nutrition programs.\nFunding for the study was provided by Wakunaga of America Co., Ltd., the producer of Kyolic Aged Garlic Extract.\nFollowing evaluation, the participants were given either a placebo or a dose of 2,400 milligrams of Aged Garlic Extract every day.\n", "question": "Does the news release establish the availability of the treatment/test/product/procedure?", "explanation": "The Aged Garlic Extract\u00a0mentioned in the release is readily available at health food stories and other venues.", "answer": 1}, {"article": "All were treated with medicines that improve chest pain and heart and artery health such as aspirin, cholesterol-lowering statins, nitrates, ACE inhibitors, beta-blockers and calcium channel blockers.\nResearchers from Canada and the United States followed more than 2,200 patients who had symptoms of heart disease but were considered stable, reports CBS News medical correspondent Dr. Jon LaPook.\nA tiny balloon is inflated to flatten the clog and a mesh scaffold stent is usually placed.\n\"Few would have expected such results.\"\nThose patients now should try drugs first, experts say.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story clearly states that stenting is very common in the U.S.", "answer": 1}, {"article": "A colonoscopy isn\u2019t something you get just for giggles. Beyond the obvious unpleasantness, there\u2019s the small but real risk of complications that in rare cases can lead to hospitalization or even death.\n\nThat\u2019s why the American Cancer Society and other groups recommend that people screened for colorectal cancer using a colonoscopy wait a decade in between tests if no polyps or other signs of potential cancer are found. Polyps are slow-growing, and the benefits of being screened more frequently than that don\u2019t seem to outweigh the risks \u2026", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The availability of colonoscopies is not in question.", "answer": 2}, {"article": "Sexual health charity the FPA, Fertility UK, and the Faculty of Sexual and Reproductive Health of the Royal College of Obstetricians and Gynaecologists are jointly calling for more large-scale independent trials to ensure that evidence for such apps is on a par with other rigorously tested methods of contraception.\nThe app was approved as a class IIb medical device by T\u00fcv S\u00fcd, a notified body in Sweden where it is based.\nAnd if the app gives you a \"red day\" \u2013 meaning you could be fertile \u2013 you have to abstain from sex, or use another method of protection such as condoms.\nAt first she starts to use the app to prevent pregnancy, and when she's ready [to get pregnant] she switches to plan, and usually she gets pregnant quite quickly, because the app already knows her body and cycle.\"\nTaking your temperature is what sets Natural Cycles and other apps like it apart from standard period-tracking apps.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "The story names the company that produces the app and links to the company\u2019s website. It also mentioned the regulatory status of the device in Sweden where the company is based.", "answer": 1}, {"article": "Parents get frustrated with the FDA recommendations not to use cold medicines in kids under the age of 4 because they are left with few options.\nThe current study shows that Vaporub is more effective than placebo.\"\nOnly children with moderate cough and severe stuffy nose were eligible, and those were divided into three groups.\nParents were surveyed the day before treatment about the severity of their child's symptoms.\nVicks VapoRub is not recommend for children under the age of 2.\n", "question": "Does the story establish the availability of the treatment/test/product/procedure?", "explanation": "\n\n\nThe availability of VapoRub is well known.", "answer": 1}]